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thesis focuses on developing statistical models and methods for analysis of high throughput genomic and
transcriptomic sequencing data with the goal of finding actionable targets of two types, disease-associated
genes and disease-implicated cell types.
Traditional genome wide association studies(GWAS) focus on finding the association between genetic
variants and diseases. However, GWAS results are often difficult to interpret, and they do not directly lead to
an understanding of the true biological mechanism of diseases. Following GWAS findings, we can study the
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variables to estimate the causal effect of a given exposure to disease outcome. In this thesis, we introduced the
concept of ``localizable exposures'', which are exposures that can be localized, or mapped, to a specific region
in the genome, such as the expression of a single gene or the methylation of a specific loci. With sequencing
technology, allele specific reads are observable for localizable exposures, which allow their quantifications in
an allele-specific manner. In the first part of this thesis, we present a new model, ASMR, uses allele-specific
information for Mendelian randomization.
This thesis also develops methods for finding cell types implicated in disease through the joint analysis of bulk
and single cell RNA sequencing data. Bulk tissue sequencing is often used to probe genes that have tissue-level
expression changes between biological cohorts. However, tissue are usually a mixture of multiple distinct cell
types and the tissue-level changes are due to shifts of cell type proportions as well as cell type specific
expression changes. Single-cell RNA sequencing (scRNA-seq) allows the investigation of the roles of
individual cell types during disease initiation and development. We present MuSiC, a method that utilizes
cell-type specific gene expression from single-cell RNA sequencing (RNA-seq) data to characterize cell type
compositions from bulk RNA-seq data in complex tissues. When applied to pancreatic islet and whole kidney
expression data in human, mouse, and rats, MuSiC outperforms existing methods, especially for tissues with
closely related cell types. With MuSiC-estimated cell type proportions, we propose a reverse estimation
procedure that can detect cell type specific differential expression, allowing for the elucidation of the roles of
genes and cell types, as well as their interactions, on disease phenotypes.
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ABSTRACT
MENDELIAN RANDOMIZATION AND SINGLE CELL DECONVOLUTION, TWO
PROBLEMS IN STATISTICS GENETICS
Xuran Wang
Nancy R. Zhang
Finding interpretable targets within the genome for diseases is a primary goal of biomedical
research. This thesis focuses on developing statistical models and methods for analysis
of high throughput genomic and transcriptomic sequencing data with the goal of finding
actionable targets of two types, disease-associated genes and disease-implicated cell types.
Traditional genome wide association studies(GWAS) focus on finding the association be-
tween genetic variants and diseases. However, GWAS results are often difficult to interpret,
and they do not directly lead to an understanding of the true biological mechanism of
diseases. Following GWAS findings, we can study the causal effect by Mendelian random-
ization(MR), which uses segregating genomic loci as instrumental variables to estimate the
causal effect of a given exposure to disease outcome. In this thesis, we introduced the con-
cept of “localizable exposures”, which are exposures that can be localized, or mapped, to a
specific region in the genome, such as the expression of a single gene or the methylation of a
specific loci. With sequencing technology, allele specific reads are observable for localizable
exposures, which allow their quantifications in an allele-specific manner. In the first part of
this thesis, we present a new model, ASMR, uses allele-specific information for Mendelian
randomization.
This thesis also develops methods for finding cell types implicated in disease through the
joint analysis of bulk and single cell RNA sequencing data. Bulk tissue sequencing is often
used to probe genes that have tissue-level expression changes between biological cohorts.
However, tissue are usually a mixture of multiple distinct cell types and the tissue-level
v
changes are due to shifts of cell type proportions as well as cell type specific expression
changes. Single-cell RNA sequencing (scRNA-seq) allows the investigation of the roles of in-
dividual cell types during disease initiation and development. We present MuSiC, a method
that utilizes cell-type specific gene expression from single-cell RNA sequencing (RNA-seq)
data to characterize cell type compositions from bulk RNA-seq data in complex tissues.
When applied to pancreatic islet and whole kidney expression data in human, mouse, and
rats, MuSiC outperforms existing methods, especially for tissues with closely related cell
types. With MuSiC-estimated cell type proportions, we propose a reverse estimation pro-
cedure that can detect cell type specific differential expression, allowing for the elucidation
of the roles of genes and cell types, as well as their interactions, on disease phenotypes.
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CHAPTER 1 : Introduction
A central goal in biomedical research is to study the genome and find genes and other
biological features that are responsible for diseases. Here we refer to such features on which
downstream experiments can be performed to interpret, validate, quantify, and isolate their
functional effects as actionable targets. In this thesis, we developed statistical models and
computational methods for finding actionable targets using genetic and genomic data. The
targets that we consider include the RNA expression of specific gene and the representation
of specific cell types in tissue.
1.1. Allele specific Mendelian randomization
In genetics, Genome-wide association studies (GWAS) have been the stable of research
for the last twenty years, since the sequencing of human genome allowed for the mapping
to genes. The goal of GWAS is to find associations between genetic variants, such as
single-nucleotide polymorphisms (SNPs), and observable traits such as diseases. The first
successful GWAS published in 2002, found the association between LTA and myocardial
infarction (Ozaki et al., 2002). Up until now, we have mapped over a hundred thousand
genetic variants to various diseases, for example DRD2 to schizophrenia, PADI4 and IL6R
to rheumatoid arthritis, and more (Visscher et al., 2017). Mapping diseases to genes and
performing downstream analysis allow us to find treatments to diseases with gene knock-
outs, gene editing and developing drugs.
The goal of GWAS is to find genes that are causally implicated in diseases by mapping
diseases onto genetic variants. However, association between genetic variants and diseases
is not enough to establish causal relationships or to explain the underlying biological mech-
anism. From the central dogma of biology, RNA is the intermediate molecule that leverages
the effect of genetic variants to disease phenotypes. This motivates the study of expression
quantitative traits loci (eQTL), defined as genomic loci that explain all or a fraction of
the variation in the expression levels of mRNAs. The identification of disease associated
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loci and their characterization as eQTLs allow us to quantify the causal effect of gene on
disease phenotypes. The use of inherited genetic variation to study the causal effect of an
exposure on a trait is called Mendelian randomization (MR). In this thesis, we consider
the use of localizable exposures, which we define as exposures that can be localized to a
specific region in the genome. For example, we can think of gene expression or epigenetic
modification as an “exposure” in the terminology of epidemiologists, and since they can
be directly mapping to a genome location, they are localizable exposures. With sequenc-
ing techniques, allele specific reads at heterozygous loci are observable, which allow the
allele-specific quantifications of localizable exposures. We developed a method, ASMR,
that incorporates the allele-specific information in a Mendelian randomization framework
to estimate the causal effect of localizable exposure using maximum likelihood. A compar-
ison of precision between two-stage-least-square (2SLS), a conventional estimation method
for MR, and ASMR is presented with different strength of instrumental variables and con-
founder effects. We also illustrate how to find downstream targets of lncRNA using ASMR.
This work is described in Chapter 2.
1.2. Cell type contributions to diseases
Unlike genetics, which focuses on segregating genetic variants and their affected genes, ge-
nomics is a relatively newer field that involves the whole genome and its quantitative behav-
iors. The technological evolution in whole genome RNA and DNA sequencing have allowed
for genomic studies. A common type of analysis useful in genomics is differential expression
analysis (Costa-Silva et al., 2017), which takes gene expression data to detects quantitative
changes in expression levels between groups of samples such as between disease cohorts. Es-
sentially, for each gene, statistical tests have been developed to decide whether an observed
difference in expression between two cohorts is greater than the expected difference due to
random variation. Large-scaled bulk tissue RNA and DNA sequencing datasets, such as
Genotype-Tissue Expression (GTEx) Project (Carithers et al., 2015), have been generated,
which allows tissue-specific investigation on diseases. However, bulk tissue sequencing data
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reflects an average over all cells within the tissue, masking the contribution of individual
cell types. It was difficult to sequence at the single cell level before 2009, because it was
hard to isolate individual cells, and because the abundance of RNA in a single cell is too
little to sequence. Recent advances in the techniques for isolating single cells and for am-
plifying their genetic material make possible the exploration of the transcriptome of single
cells. With the birth of single-cell sequencing, researchers can study the transcriptomic
heterogeneity of a single cell for thousands to millions of cells simultaneously.
“Cell type” is a classification used to distinguish between morphologically or phenotypically
distinct cell forms. Usually complex tissues consist of cells of different cell types; for example
in the human pancreas, there are endocrine cell types and exocrine cell types that jointly
regulate glucose level. Cells of the same type show similar transcriptomic pattern, which
can be captured by single cell RNA-seq data. Annotating cell types based on single-cell
transcription profiles is a challenging problem and can be viewed as high-dimensional un-
supervised clustering with high level of biological and technical noises. Currently, popular
clustering methods include Seurat (Butler et al., 2018), TSCAN (Ji and Ji, 2016) and SC3
(Kiselev et al., 2017) (more in the recent review by Duo` et al. (2018)). After clustering,
the cell types are identified by their marker genes, which are genes that only express in a
specific cell type. Based on cell types assigned in this way, we can study the inter- and
intra-cell-type similarity and heterogeneity from single cell sequencing data and develop
methods to study the role of cell types in diseases.
The observed differential expression in bulk tissue is a combined effect of cell type com-
position shifts and the expression shifts within cell types. Therefore, investigating the
differences between groups of samples at the cell type levels can be framed as two problems,
detecting cell type composition shifts and detecting cell type specific differentially expressed
(DE) genes. Finding cell type specific DE genes is especially challenging because there is
confounding from proportion shifts. One may ask, with the rapid adoption of of single cell
sequencing, why not use single cell data to investigate cell-type level differences. However,
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due to cell loss in the dissociation and isolation steps of single cell sequencing, proportions
from single cell data do not reflect the true proportions in bulk tissue. Therefore, we and
others(Avila Cobos et al., 2018) proposed the strategy of first estimating cell type propor-
tions of bulk tissues with single cell expression as reference. Such estimation procedures
are often referred as deconvolution. There are many existing deconvolution methods, such
as CIBERSORT (Newman et al., 2015) and BSEQ-sc (Baron et al., 2016). However, they
only use marker genes for estimation and ignore the cross-subject variations of gene expres-
sion when multi-subject single cell datasets are available. We developed a method, MuSiC,
that takes the advantage of cross-subject variations of all genes in deconvolution without
selecting marker genes. This is discussed in Chapter 3.
Now let’s go back to the question of how to detect cell type specific differential expression
from bulk tissue. Cell type specific differential expression testing starts from estimating cell
type proportions by deconvolution guided with single cell reference. Deconvolution methods
with pre-selected marker genes assume that the expression of marker genes are consistent
across healthy and diseased status, which is not always true. For example, in pancreas
islet, INS is the genes responsible for producing insulin and is a marker gene for beta cells.
During the progress of type 2 diabetes, beta cells go through both loss of mass and lack
of function, where there are less beta cells as well as lower INS expression in beta cells for
diseased subjects. Although the expression of INS is higher in beta cells than other cell
types, deconvolution with only marker genes like INS will mistaken the cell type specific
expression changes for cell type proportion shifts. MuSiC eliminates the bias from marker
genes by including all genes for deconvolution. Controlling the estimated proportion from
MuSiC makes it possible to detect cell type specific DE genes between healthy and diseased
status. We proposed a method for testing cell type specific DE genes by comparing two cell
type models with and without disease indicator with a strategy of repetition partition of
genes in to a set used for deconvolution and a separate set on which DE test is conducted.
This is described in Chapter 4.
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CHAPTER 2 : Allele specific Mendelian randomization
2.1. Introduction
A common goal of biomedical research is to elucidate the causal roles of genetic and epi-
genetic factors underlying complex human diseases. Mendelian randomization (MR) is a
method for estimating the causal effect of an intermediate variable on an outcome of in-
terest, in which inherited DNA variation are used as instrumental variables to overcome
the effect of confounding and reverse causation. Mendelian randomization was adopted as
early as 1986, when Katan (2004) used genetic marker ApoE as instrument for studying the
causal effect of raised blood cholesterol on risk of cancers. Now it has been widely applied
to epidemiology and integrative genetics models, more in the review paper by Burgess et al.
(2017). For example, to measure the causal effect of alcohol consumption on the risk of
coronary heart disease, the genetic variant ALDH2, which reduces alcohol consumption,
has been used as an instrument (Smith and Ebrahim, 2004). In integrative genetics models,
a large number of transcript abundances are measured with the ultimate aim of identify-
ing causal relationships from a morass of expression quantitative trait loci (eQTL) using
Mendelian randomization. For other examples, see recent review by Burgess and Thompson
(2015).
To date, the “modifiable exposure” examined by Mendelian randomization studies have
encompassed blood pressure, obesity, smoking, alcohol intake etc. Increasingly, with the
ubiquitous adoption of high throughput sequencing technologies, the “exposure” of interest
can now also focus in on the expression of a single gene or the methylation of a specific
loci. We call such exposures localizable exposures, in that they can be localized, or
mapped, to a specific region in the genome. High throughput sequencing has revolutionized
the study of the transcriptome and the epigenome. One important benefit of sequencing
is that it quantifies gene expression or epigenetic modification in an allele-specific manner,
such that at heterozygous loci, the sequenced read indicates which locus it comes from. For
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example, in RNA sequencing, this allows us to measure the number of transcript copies of
each allele. This allele-level information has not, to our knowledge, been used in Mendelian
randomization studies. We will develop a method for using such allele-level information and
show that it can substantially boost estimation accuracy. Although this chapter focuses
on gene expression, the methods we propose can be applied to other types of localizable
exposures, such as methylation or splicing.
The measurement of allele-specific information in heterozygous individuals enables us to
compare the difference between expressions of two paired alleles and consider expression
level of different genotypes in a causal inference manner, where the causal effect is the
difference between potential outcomes of the same subject. With the same idea, we use
“dosage” to describe the difference between potential expressions of different alleles at the
same loci, thus dosage measures the causal effect of changing the allele. The causal effect
can not be measured directly because at each loci, at each haplotype, only one of the
two potential outcomes can be observed. Even for heterozygous individuals, where the
expression of both allele can be observed, the expression of each allele is a separate random
variable which may be correlated due to the sharing of common environment, but cannot
be considered to have the same potential outcomes.
The focus on localizable exposues has the additional benefit of allowing us to more easily
satisfy the assumptions of Mendelian Randomization. The use of DNA-level variations
as instrumental variables relies on two basic assumptions: First, the DNA variant must
be stably maintained in our cells and not correlated with lifestyle and environment; this
assumption is reasonable in most cases after proper adjustment for genetic ancestry. Second,
the DNA variant must affect the outcome only through the exposure of interest, and this
assumption is often violated, and very difficult to check due to pleiotropy. However, when
the modifiable exposure is localizable, we can select to use only genetic variants that are
physically close to the exposure on the genome. In genetics terminology, we limit our
instruments to variants that affect the exposure in cis, as opposed to variants that act in
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trans.
The classical approach for analyzing the causal effect in Mendelian randomization is two-
stage least squares (2SLS). As long as the instrumental variable satisfies the assumptions for
being a valid instrument, 2SLS gives consistent estimates of the causal effect of the exposure
on outcome. In this chapter we propose an alternative method for estimating the causal
effect of a localizable exposure on a quantitative phenotype. This chapter is organized as
follows: In Section 2.2, we introduced the additive linear model and our notation. In Section
2.3, we described the model assumption and estimation procedure. Simulation results are
shown in Section 2.4 to compare the powers of the proposed method to 2SLS. We illustrated
the new framework to an example applicable in finding downstream regulatory targets of
lncRNA in the data from the Geuvadis project (Lappalainen et al., 2013). A summary is
given in Section 2.6. To simplify language, we use interchangeably localizable exposure and
gene expression, since the latter is our primary example.
2.2. Model set up and notations
2.2.1. Model overview
Figure 1 shows the relationship between the key variables of our model. Let Ti denote the
total expression level for the gene of interest for individual i, i ∈ {1, 2, . . . , n}. Yi is the
observed quantitative outcome for individual i and our goal is to estimate the causal effect
of changing Ti on the outcome Yi. Assume a simple linear model:
Yi = βTi + Vi (2.1)
in which β represents the causal effect and Vi the total contribution of unobserved covariates
and measurement errors. One could also extend the model to include possible observed
covariates, but since we would be able to control for these by taking partial regression
residuals, leading us back to (2.1), we keep things simple by ignoring observed covariates
for now. We will use bold upper case un-subscripted letters to denote the vectors containing
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Figure 1: Diagram of allele specific Mendelian randomization model for (a) homozygous
individuals and (b) heterozygous individuals.
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the individual observations, T = (T1, . . . , Tn)
T and Y = (Y1, . . . , Yn)
T .
We assume that within the transcribed region of the gene there is a SNP loci, which we
call the tagging SNP, and that located outside the transcribed region in cis to the gene is a
regulatory SNP. We also assume that there are only two alleles for each SNP and that the
phase between these two SNPs is known. In other words, we assume that the haplotypes
are known.
The observed total expression, denoted as Xi, differs from true expression level Ti by mea-
surement error ei. For individuals that are heterozygous at the tagging SNP, we observe
the expressions of its two alleles,
Xi1 = Ti1 + ei1
and Xi2 = Ti2 + ei2,
(2.2)
as well as the observed total expression Xi = Xi1 + Xi2; for homozygous individuals, only
the total expression Xi = Ti+ ei can be observed. Let Zi1, Zi2 ∈ {0, 1} be the two inherited
alleles at the regulatory SNP for individual i. When both the tagging and the regulatory
SNPs are heterozygous, let Zi1 and Zi2 correspond to the allele on the haplotype with
expression Ti1 and Ti2, respectively. We assume the additive model for the effect of the
regulatory SNP on the expression of its linked allele,
Tij = Ui +W
(j)
i Zij j = 1, 2 (2.3)
in which j ∈ {1, 2} indexes the haplotype and W (j)i Zij is the dosage effect of having the
“1” haplotype on expression level Tij . We assume independent cis regulatory effects, which
means W
(1)
i is independent with W
(2)
i .
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2.2.2. Two stage least squares method for estimation β
A standardized regression of Y on X would yield a biased estimate for the causal effect β.
This is due to existence of measurement error and correlation between U and V . To attain
an unbiased estimate, the most widely used method is two-stage least squares (2SLS), which
will be taken as the baseline for comparisons.
2SLS estimates the causal effect β by first forming a prediction for X based on the in-
strument Z, and then regressing Y on XZ . In detail, let X˜ = X − X¯, Y˜ = Y − Y¯ and
Z˜ = Z− Z¯, the projection of X on Z is
XZ = X¯ + (Z˜
′Z˜)−1Z˜′X˜, (2.4)
and the 2SLS estimate of β is
βˆ2SLS = (X˜
′
ZX˜Z)
−1X˜′ZY˜. (2.5)
The two-stage least squares estimate is a consistent estimator for β in our model, but
ignores the information in the allele-specific measurements Xi1, Xi2 for individuals that are
heterozygous at the tagging SNP.
2.3. Estimation of causal effect in allele-specific model
The model described in Section 2.2.1 is a general model void of distribution assumptions.
Here we add specific assumptions on the distribution of Z, U , V and W to allows maximum
likelihood estimation of the causal parameter β.
2.3.1. Distribution assumptions
Assume genotype Zij follows Bernoulli distribution with minor allele frequency P (Zij =
1) = p ∈ (0, 1). Without loss of generality, let Zi1 = 1 and Zi2 = 0 when individual i is
heterozygous (Zi = 1).
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In (2.3), the independence of confounder Ui and dosage W
(j)
i is assumed. This means that
by changing the regulatory SNP’s genotype Zij , the expression difference is independent
of confounder effects contributing to the expression. This is a critical assumption for the
instrumental variable to be a valid one. This assumption is not expected to always be true
and even worse, it is usually hard to verify. With allele specific model, this assumption can
be partially checked by Xi1−Xi2s and Xi1s from heterozygous individuals, see Figure 5 for
examples. It is intuitive to consider that in (2.1), Vi, the total contribution of unobserved
covariates and measurement errors on the outcome, is also independent of W
(j)
i . We assume
that W
(j)
i is i.i.d. normal with mean µw and variance σ
2
w, and that the joint distribution of
(Ui, Vi) is i.i.d. bivariate normal with correlation ρ,Ui
Vi
 ∼ N(
µu
µv
 ,
 σ2u ρσuσv
ρσuσv σ
2
v
).
Measurement error e in (2.2) is independent of the other variables. For each observation,
measurement error follows N(0, σ2e). That is, instead of observing Tij or Ti, we observe
Xij = Tij + eij and Xi = Ti + ei.
Given the observed distribution assumptions, the distribution for the observed data
{Zi, Xi, Yi} for homozygous and {Zi, Xi1, Xi2, Yi} for heterozygous as follows:
For (Zi1, Zi2) = (0, 0), i.e. homozygous individuals for the (0, 0) haplotype,
(Yi − βXi, Xi)T ∼ N((µv, 2µu)T ,Σ1); (2.6)
for heterozygous individuals (Zi1, Zi2) = (1, 0),
(Yi − βXi, Xi, Xi1 −Xi2)T ∼ N((µv, 2µu + µw, µw)T ,Σ2); (2.7)
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for homozygous individual (Zi1, Zi2) = (1, 1),
(Yi − βXi, Xi)T ∼ N((µv, 2µu + 2µw)T ,Σ3). (2.8)
The covariance matrices in (2.6-2.8) are as follows,
Σ1 =
 σ2v+β2σ2e 2ρσuσv−βσ2e
2ρσuσv−βσ2e 4σ2u+σ2e
 ,
Σ2 =

σ2v+2β
2σ2e 2ρσuσv−2βσ2e 0
2ρσuσv−2βσ2e 4σ2u+σ2w+2σ2e σ2w
0 σ2w σ
2
w+2σ
2
e
 ,
Σ3 =
 σ2v + β2σ2e 2ρσuσv−βσ2e
2ρσuσv−βσ2e 4σ2u + 2σ2w + σ2e

(2.9)
2.3.2. Identifiability
Nine parameters are used to describe the distribution of the observed variables: 3 param-
eters (µu, µv, µw) for the mean of U, V,W ; 5 parameters for the variances and covariance:
(σ2e , σ
2
v , σ
2
u, σ
2
w, ρ); and 1 parameter of the causal effect, β. There are 2 constraints: (i)
variances are non-negative σ2e ≥ 0, σ2v ≥ 0, σ2u ≥ 0, σ2w ≥ 0; (ii) the correlation ρ is between
−1 and 1.
From (2.6-2.8), the model is in the form of an exponential family. Therefore, to check
identifiability we only need to evaluate the determinant of the Fisher information matrix
R:
R = (Rjk), Rjk = E[
∂l
∂θj
∂l
∂θk
] (2.10)
where l is the log-likelihood function, θ = (µu, µv, µw, σ
2
v , σ
2
e , σ
2
u, σ
2
w, ρuv, β) and ρuv =
ρσuσv. If R is nonsingular in a convex set within the feasible parameter space, then every
parameter point θ in the feasible parameter space is globally identifiable (Rothenberg et al.,
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1971).
Let p1 = σ
2
v+β
2σ2e , p2 = 2ρσuσv−βσ2e , and p3 = 4σ2u+σ2e and replace the parameters θ with
θ∗ = (µu, µv, µw, p1, p2, p3, σ2e , σ2w, β). The Jacobian matrix between variance covariance
parameters (p1, p2, p3, σ
2
e , σ
2
w, β) and (σ
2
v , σ
2
e , σ
2
u, σ
2
w, ρuv, β) is
∂(p1, p2, p3, σ
2
e , σ
2
w, β)
∂(σ2v , σ
2
e , σ
2
u, σ
2
w, ρuv, β)
=

1 β2 0 0 0 2βσ2e
0 −β 0 0 2 −σ2e
0 1 4 0 0 0
0 1 0 0 0 0
0 0 0 1 0 0
0 0 0 0 0 1

. (2.11)
The Jacobian matrix is non-singular with determinant 8. This means that if θ∗ is identifi-
able, then so is θ.
Rewriting the distribution (2.6-2.8) using the parameters θ∗, for homozygous (Zi1, Zi2) =
(0, 0) individuals,
(Yi − βXi, Xi)T ∼ N((µv, 2µu)T ,Σ∗1), (2.12)
for heterozygous (Zi1, Zi2) = (1, 0) individuals,
(Yi − βXi, Xi, Xi1 −Xi2)T ∼ N((µv, 2µu + µw, µw)T ,Σ∗2), (2.13)
for homozygous (Zi1, Zi2) = (1, 1) individuals,
(Yi − βXi, Xi)T ∼ N((µv, 2µu + 2µw)T ,Σ∗3), (2.14)
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with covariance matrices
Σ∗1 =
p1 p2
p2 p3
 ;
Σ∗2 =

p1+β
2σ2e p2−βσ2e 0
p2−βσ2e p3+σ2w+σ2e σ2w
0 σ2w σ
2
w+2σ
2
e
 ;
Σ∗3 =
p1 p2
p2 p3 + 2σ
2
w
 .
(2.15)
The observed data can be divided by genotypes into 3 groups. The observations (Xi, Xi1, Xi2, Zi, Yi)
are independent across individuals, and individuals within same group follow the same dis-
tribution (2.12-2.14). Therefore the log-likelihood function of the whole population can be
written as the sum of the log-likelihood functions for each group: l∗ = l∗1 + l∗2 + l∗3.
The Fisher information matrix, expressed in terms of the new parameters θ∗, is
R∗ = (R∗jk), R
∗
jk = E[
∂l∗
∂θ∗j
∂l∗
∂θ∗k
] (2.16)
R∗jk =E[
∂l∗
∂θ∗j
∂l∗
∂θ∗k
]
=E[
∂(l∗1 + l∗2 + l∗3)
∂θ∗j
· ∂(l
∗
1 + l
∗
2 + l
∗
3)
∂θ∗k
]
=
3∑
s=1
E[
∂l∗s
∂θ∗j
∂l∗s
∂θ∗k
] + (
∂l∗1
∂θ∗j
· ∂l
∗
2
∂θ∗k
+
∂l∗1
∂θ∗k
· ∂l
∗
2
∂θ∗j
)
+ (
∂l∗2
∂θ∗j
· ∂l
∗
3
∂θ∗k
+
∂l∗2
∂θ∗k
· ∂l
∗
3
∂θ∗j
) + (
∂l∗3
∂θ∗j
· ∂l
∗
1
∂θ∗k
+
∂l∗3
∂θ∗k
· ∂l
∗
1
∂θ∗j
).
(2.17)
Note that E[
∂l∗s
∂θ∗j
· ∂l
∗
t
∂θ∗k
] = E[
∂l∗s
∂θ∗j
] · E[ ∂l
∗
t
∂θ∗k
] when s 6= t. E[ ∂l
∗
s
∂θ∗j
] = 0 for all s = 1, 2, 3 and
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j = 1, . . . , 9. Therefore
R∗jk = E[
∂l∗
∂θ∗j
∂l∗
∂θ∗k
] =
3∑
s=1
E[
∂l∗s
∂θ∗j
∂l∗s
∂θ∗k
]
Let R∗(s), s = 1, 2, 3 denote the Fisher information matrix for each genotype group, R∗ =
R∗(1)+R∗(2)+R∗(3). Individuals in the same group have independent identical distribution,
and consequently, the same log-likelihood function. Take the first group (Zi = 0) as example:
l∗1 =
∑
i:Zi=0
l
∗(i)
1
where l
∗(i)
1 is the log-likelihood function of individual i in the first group.
R
∗(1)
jk = E[(
∑
i:Zi=0
∂l
∗(i)
1
∂θ∗j
)(
∑
i:Zi=0
∂l
∗(i)
1
∂θ∗k
)]
=
∑
i:Zi=0
E[
∂l
∗(i)
1
∂θ∗j
· ∂l
∗(i)
1
∂θ∗k
] = N1 · E[∂l
∗(i)
1
∂θ∗j
· ∂l
∗(i)
1
∂θ∗k
].
We denote N1, N2 and N3 as the sample size of genotype Zi = 0, Zi = 1, and Zi = 2
correspondingly. N1 +N2 +N3 = N .
Proposition 2.1 Let G∗1 denote the Fisher information matrix for each individual in the
first group and R∗(1) = N1G∗1. Similarly, G∗2 and G∗3 are the Fisher information matrix for
individuals in second and third group.
(a) rank(G∗1) = 5, det(G∗1) = 0; the identifiable parameters are: (µv, µu, p1, p2, p3);
(b) rank(G∗3) = 5, det(G∗3) = 0; the identifiable parameters are: (µv, µu + µw, p1, p2, p3 +
σ2w);
(c) rank(G∗2) = 9 with
det(G∗2) =
219σ4w
det(Σ∗2)5
;
det(G∗2) 6= 0 when σ2w 6= 0 and Σ∗2 6= 0;
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(d) rank(N1G
∗
1 + N3G
∗
3) = 8, det(N1G
∗
1 + N3G
∗
3) = 0 for all N1, N3 ∈ N; the identifi-
able parameters are: θ˜ = (µv, µu, µw, p1, p2, p3, σ
2
w, β); Let G˜1 and G˜3 be the Fisher
information matrix of homozygous observations corresponding to parameter θ˜. And
the Fisher information matrix with only homozygous individuals is as follows:
det [N1G˜1 +N3G˜3]
=
221N31N
3
3 (N1 +N3)p
2
1((N1 +N3)p1σ
2
w + µ
2
w(N3 det(Σ
∗
1) +N1 det(Σ
∗
3)))
det(Σ∗1)4 det(Σ∗3)4
(e) rank(R∗) = 9, det(R∗) = det(N1G∗1 + N2G∗2 + N3G∗3) 6= 0, if N2 6= 0 because the
numerator of det(R∗) is proportionate to N2.
Thus, as long as both homozygous genotypes are observed (N1N3 6= 0), and the gene has a
non-zero effect on either mean or variance of expression level (σ2w and µw is not zero at the
same time), the model is identifiable for θ˜. Although we can not estimate σ2e from θ˜, β, as
well as p1, p2 p3, σ
2
w and µ, are identifiable. All parameters are identifiable when N2 > 0,
that is, if we can observe heterozygous individuals.
2.3.3. Maximum likelihood estimation
The full log-likelihood function follows exactly the joint distribution (2.6-2.8). Let µ =
(µu, µv, µw), σ = (σ
2
e , σ
2
v , σ
2
u, σ
2
w, ρ), the log-likelihood is
l1(µ,σ, β,X, Y, |Z = 0) = −1
2
∑
Zi=0
{
log(|Σ1|)
− 1
2
Yi−βXi−µv
Xi−2µu

T
Σ−11
Yi−βXi−µv
Xi−2µu
}, (2.18)
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l2(µ,σ, β,X, Y, |Z = 1) = −1
2
∑
Zi=1
{
log(|Σ2|)
− 1
2

Yi−βXi−µv
Xi−2µu−µw
Xi1−Xi2−µw

T
Σ−12

Yi−βXi−µv
Xi−2µu−µw
Xi1−Xi2−µw
},
(2.19)
l3(µ,σ, β,X, Y, |Z = 2) = −1
2
∑
Zi=2
{
log(|Σ3|)
− 1
2
 Yi−βXi−µv
Xi−2µu−2µw

T
Σ−13
 Yi−βXi−µv
Xi−2µu−2µw
}, (2.20)
where Σ1, Σ2 and Σ3 are defined in (2.9). We used the optim function directly from R to
get the estimated parameters with maximum likelihood. Here, we define this method as
ASMR, refer to Allele Specific Mendelian Randomization estimation.
2.4. Simulation study
The variance of true expression level Ti is composed of the variance due to genotype Zi
as W
(1)
i Zi1 + W
(2)
i Zi2 and the variance of Ui, according to (2.3). Compare the variance
accounts for genotype Zi,
Var[W
(1)
i Zi1 +W
(2)
i Zi2] = 2Var[W
(1)
i Zi1]
= 2(pσ2w + p(1− p)µ2w).
(2.21)
with the variance of observed expression level Xi,
Var[Xi] = E[Var[Xi|Zi]] + Var[E[Xi|Zi]]
= 4σ2u + σ
2
e + 2(pσ
2
w + p(1− p)(µ2w + σ2e)).
(2.22)
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The variance of the confounder U (σu), which contributes to the expression, is taken as
the standard to measure other parameters: µw/σu, σw/σu, and σe/σu. Therefore in every
simulation, we are going to fix σu = 1. We are also going to fix µu = 1 and µv = 0 while
changing other parameters.
To measure the strength of instruments, we used the concentration parameter by Stock
et al. (2002), defined as:
µ2c =
E[(W
(1)
i Zi1 +W
(2)
i Zi2)
2]
4σ2u
= p
(µ2w
σ2u
+
σ2w
2σ2u
)
. (2.23)
When µ2c is greater than 1.82, the instrument can be considered as strong.
The classical estimation method, 2SLS estimation, is used to evaluate the performance of
ASMR proposed in Section 2.3. Theoretically, 2SLS estimation is unbiased with asymptotic
variance
Var[βˆ2SLS ] =
1
n
M−1XZE[XiZ
′
i]E[ZiZ
′
i]
−1E[(Yi − βXi)2ZiZ ′i]E[ZiZ ′i]−1E[XiZ ′i]′M−1XZ (2.24)
in which MXZ = E[XiZ
′
i]E[ZiZ
′
i]
−1E[XiZ ′i]
′. Var[βˆ2SLS ] does not depends on σ2w, the
variance of the dosage.
The performance of ASMR and 2SLS are measured by the medians of estimated causal
effect and the median absolute difference between true and estimated causal effect across
nsim = 1000 simulations of n = 1000 individuals. Data is generated from distribution (2.6-
2.8). In each simulation setting, we varied the confounding effect ρ from 0 (no confounding)
to 1 (fully confounded). Across simulation settings, we change the strength of instruments
by varying the mean and variance of dosage, µw and σ
2
w and the results are shown in Figure
2-3.
We changed the strength of instrument by varying the mean of dosage µw (Figure 2a and
b) while fix other parameters: true causal effect β = 1, minor allele frequency p = 0.1,
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variance of dosage σ2w = 1 and the variance of confounders σ
2
v = 1, σ
2
u = 1. The strength is
considered strong when µw = 6 and µw = 2, and weak when µw = 0.5. We also examined
median strength IV with µw = 1.
Comparing the median of estimated causal effect and true causal effect, in general, 2SLS
and ASMR methods are both approximately unbiased across the range of the confounder
strength ρ. The estimates are more accurate across ρ with stronger instruments (Figure
2b). The stronger the instrument is, the smaller difference between true and estimated
causal effect for both 2SLS and ASMR methods (Figure 2a). When the instrument is weak
(µw = 0.5), ASMR improved the estimation accuracy significantly compared with 2SLS.
The accuracy of ASMR estimation with µw = 0.5 is similar with 2SLS with µw = 1. With
increasing instrument strength (µw = 1, 2 and 6), the difference of accuracy between ASMR
and 2SLS becomes smaller. When the instrument is a strong instrument (µw = 6), there is
almost no difference between ASMR and 2SLS. If the strength of instrument is too weak
(µw = 0.2) to explain the gene’s expression level X or even invalid (µw = 0), the estimation
is unacceptable with large amount of outliers for both 2SLS and ASMR (Figure 17). In
conclusion, when varying the strength of instrument by the mean of dosage, ASMR gives
more accurate estimates of causal effect than 2SLS.
The strength of instrument is determined not only by the mean of dosage, but also by
the variance of dosage σ2w (Equation (2.23)), which determines how much a genotype can
explain the true expression level. Two estimation methods are compared by the median
of estimated causal effect βˆ in Figure 3a. 2SLS and ASMR both give unbiased estimation
across different confounder effects when the correlation ρ increases from 0 to 1. We also
compared the median absolute difference |βˆ − β| of two methods (Figure 3b). The median
absolute differences do not show any change for 2SLS when σ2w increases from 0.5 to 6.
This is because the variance of 2SLS estimation is invariant regarding to σ2w, wee equation
(2.24). However, the median absolute difference for ASMR estimation gets smaller as σ2w
gets bigger. When σ2w = 0, the median absolute difference of ASMR is slightly smaller than
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Figure 2: Simulation results when changing instrument strength by the mean of dosage
µw. Under each setting, we simulated 1000 times with the range of confounder strength
ρ ∈ [0, 1].
2SLS while when σ2w = 6, the median absolute difference of ASMR is about 0.01, which is
much lower than that of 2SLS, which is around 0.06. If the variance is smaller, σ2w = 0.2,
or even no variation for dosage σ2w = 0, there are barely no difference between ASMR and
2SLS estimates (Figure 3).
In short, the results from simulations show that when the instruments are too weak to
explain the gene’s expression level or when the instruments are very strong, ASMR performs
similarly to 2SLS. When the instruments are weak and can only partially explain the gene’s
expression level, the ASMR has higher power than 2SLS.
2.5. Real data example: Finding downstream targets of lincRNA
Long intergenic non-coding RNAs (lincRNAs) have gained widespread attention in recent
years as a potentially new and crucial layer of biological regulation. lincRNAs of all kinds
have been implicated in a range of developmental processes and diseases, but knowledge of
the mechanisms by which they act is still limited. Rinn and Chang (2012) hypothesized
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Figure 3: Simulation results when changing instrument strength by the variance of dosage
σ2w. Under each setting, we simulated 1000 times with the range of confounder strength
ρ ∈ [0, 1].
that lincRNAs regulate the transcription of other genes and their mRNA expression. The
causal relations between lincRNAs and mRNAs from coding-genes have been examined in
Mendelian randomization by McDowell et al. (2016) using 2SLS, where they found signif-
icant pairs of lincRNAs and genes. For more information, see recent review by Mattick
(2018). In this section, we applied the allele specific model to real data of lincRNA and
mRNA expression, estimated causal effects by ASMR and 2SLS. We also tested the signif-
icant pairs of lincRNAs and genes from estimated causal effects with empirical variances
and false discovery rate (FDR) control.
2.5.1. Data processing
The raw data is from Geuvadis samples (Lappalainen et al., 2013), filtered by Hardy-
Weinberg equilibrium and read strand bias. There are 87 individuals available in this
dataset. Each individual has 1513 lincRNAs expressions with their tagging SNPs’ genotypes
from 1000 Genome Project (Consortium et al., 2015) and the expression levels of genes,
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measured by Fragments Per Kilobase of transcript per Million (FPKM). The expressions of
lincRNAs are measured by read counts and the allele specific information of the lincRNA
expressions are available for heterozygous individuals with respect to the tagging SNPs.
The total expressions are obtained by adding allele specific expressions together. Gene
expressions are measured by FPKM on 26144 non-zero genes.
We selected desirable SNPs before estimating causal effect to save computing time. SNPs
that: (i) can observe 3 genotypes across individuals; (ii) have over 30% of heterozygous;
(iii) have at least one non-zero heterozygous read counts; (iv) have at least one non-zero
homozygous read counts; will be chosen. After filtering, there are 321 SNPs left.
Based on concentration parameter (equation (2.23)) and simulation results, with fixed σu,
larger µw and σw lead to more accurate estimation of causal effect β. Before estimating
causal effect from full likelihood model, we first estimate σu, µw and σw by maximizing
likelihood of model (2.3). We selected genes that are strong instruments based the ratio of
estimated σw/σu and µw/σu (Figure 4). There are 6 SNPs that shows both large µw/σu ratio
and σw/σu ratio and are considered as strong instruments. The allele specific information
provided by heterozygous individuals allows us to partially check the independence between
confounder U and dosage W by looking at the the allele specific expression from different
genotypes. Assume Xi1 and Xi2 are the observed expressions for genotype Zi1 = 0 and
Zi2 = 1 of individual i. Xi1 = Ui+ ei1 and Xi2−Xi1 = W (2)i + ei2− ei1 can be viewed as an
approximation of confounder Ui and dosage W
(2)
i . We can checked the correlation between
Xi1 and Xi2 −Xi1 for the independence of confounder U and dosage W from heterozygous
individuals. As an example, we checked SNP rs11061295 in Figure 5 and the Spearman
correlation between Xi1 and Xi2 is 0.0096.
2.5.2. Estimation of causal effect
We estimate the causal effect as well as other parameters by ASMR from log-likelihoods
(equations (2.6 - 2.8)). As noted earlier, 2SLS estimation is a well-studied, unbiased method
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Figure 4: Estimated log(|µw|/σu) and log(σw/σu) from first stage likelihood of model (2.3).
The red dots are selected lincRNA SNPs with high concentration parameter. Those SNPs
are strong instruments and used for next step causal effect analysis. This step selected 6
SNPS: rs4465295, rs7971934, rs7961690, rs11061295, rs10848271 and rs9302943.
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Figure 5: Scatter plot of Xi1 vs. Xi2 −Xi1 for SNP rs11061295 with heterozygous individ-
uals. The Spearman correlation is 0.0096.
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and it is compared with ASMR results. To detect reliable causal relation between the lo-
calizable exposure and gene expression, we compare the causal effect estimated by 2SLS
(βˆ2SLS) and ASMR (βˆASMR) after filtering out ASMR results that does converge. In addi-
tion to βˆ2SLS and βˆASMR, we also calculated the standard deviation of βˆASMR by the Fisher
information matrix (see Section 2.3.2), denoted as sd(βˆASMR), under the null hypothesis,
where there is no causal effect between lincRNA expression and gene expression. We also
calculated the standard deviation of βˆ2SLS from equation (2.24), denoted as sd(βˆ2SLS).
The z-values from ASMR and 2SLS are calculated by zASMR = βˆASMR/sd(βˆASMR)and
z2SLS = βˆ2SLS/sd(βˆ2SLS) respectively. If we assume standard normality for z2SLS and
zASMR, we will reject the genes that have z-values greater than qnorm(0.975) or less than
qnorm(0.025) for the null hypothesis and consider those genes with real causal effect from
ASMR or from 2SLS. Since we are testing 26144 genes at once, we need to control for false
discovery rate (FDR) for multiple testing. We calculated the empirical null distributions
for the z-values from both ASMR and 2SLS and adjusted for multiple testing. Then, for
both methods, we select significant genes with reject level α = 0.05. Across 6 candidate
SNPs, we focus on genes that are have large z-values from ASMR or 2SLS.
Here we also take SNP rs11061295 as an example. The allele specific information allows us
to partially check the independence between the After adjusted by empirical null, there are
296 genes that are significant differ from zero from ASMR and 1975 genes from 2SLS where
22 of them are also significant from ASMR. We first plot the z-values from estimated causal
effects and standard deviations by 2SLS and ASMR (Figure 6). After adjusted by empirical
null, we selected 20 genes that are uniquely selected by ASMR or 2SLS. From the analysis
and simulations above, we are expected to select more significant genes from ASMR because
it estimates causal effect β more accurately with stronger instruments. Since both 2SLS
and ASMR are unbiased methods for estimating causal effect, we are also expected to see a
overlap between significant genes selected by ASMR and 2SLS. However, in this example,
we did not see both patterns. Take a closer look at the expression of SNP as well as the
selected significant genes. From the scales of the z-value histograms from ASMR and 2SLS,
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Figure 6: Scatter plot with histograms of the z-values from ASMR and 2SLS. The dots
represent the genes and the x-axis and y-axis are the z-values from ASMR and 2SLS,
respectively. The red line is the x = y line. We highlighted the top 20 genes that are of
high z-values from ASMR and are only significant from ASMR by green and top 20 genes
from 2SLS by blue.
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the z-values from ASMR with empirical null distribution with larger variance. Even though
the 2SLS significant genes have similar z-values from ASMR and 2SLS, the large dispersion
from ASMR empirical null distribution leads to the overlook from ASMR. The significant
genes from ASMR are with extremely high z-values while the 2SLS provides z-values that
are close to zero. This is not because that the actual estimated causal effect from ASMR
βˆASMR is larger than that from 2SLS βˆ2SLS , in fact, they are similar, but because that the
calculated standard deviation from ASMR are extremely small.
2.6. Conclusion
Mendelian randomization (MR) has been widely studied for estimate causal effect between
gene’s expression level and phenotype of interest. Two-stage least square regression, with
DNA-variants as instruments, is the classical method for MR. In this article, we look for
a new method, ASMR, that can accommodate the development of sequencing techniques
that produced allele-specific data. Maximum likelihood estimation, i.e., estimating every pa-
rameters including the one of interests under the normal assumption, has better estimation
power than classical two stage least squares (2SLS) that ignores allele specific information.
This new method incorporates the allele-specific expression in heterozygous individuals by
separating expression Xi1 and Xi2 in distribution. It would be of interest for future study
to consider the properties of maximum likelihood estimation in the non-normal setting.
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CHAPTER 3 : Bulk tissue deconvolution with single cell RNA sequencing
3.1. Introduction
Bulk tissue RNA-seq is a widely adopted method to understand genome-wide transcriptomic
variations in different conditions such as disease states. Bulk RNA-seq measures the average
expression of genes, which is the sum of cell type-specific gene expression weighted by
cell type proportions. Knowledge of cell type composition and their proportions in intact
tissues is important, because certain cell types are more vulnerable for disease than others.
Characterizing the variation of cell type composition across subjects can identify cellular
targets of disease, and adjusting for these variations can clarify downstream analysis.
The rapid development of single-cell RNA-seq (scRNA-seq) technologies have enabled cell
type-specific transcriptome profiling. Although cell type composition and proportions are
obtainable from scRNA-seq, scRNA-seq is still costly, prohibiting its application in clinical
studies that involve a large number of subjects. Furthermore, scRNA-seq is not well suited
to characterizing cell type proportions in a solid tissue, because the cell dissociation step is
biased towards certain cell types (Park et al., 2018).
Computational methods have been developed to deconvolve cell type proportions using cell
type-specific gene expression references (Park et al., 2018). CIBERSORT (Newman et al.,
2015), based on support vector regression, is a widely used method designed for microarray
data. More recently, BSEQ-sc (Baron et al., 2016) extended CIBERSORT to allow the
use of scRNA-seq gene expression as a reference. TIMER (Li et al., 2016), developed
for cancer data, focuses on the quantification of immune cell infiltration. These methods
rely on pre-selected cell type-specific marker genes, and thus are sensitive to the choice of
significance threshold. More importantly, these methods ignore cross-subject heterogeneity
in cell type-specific gene expression as well as within-cell type stochasticity of single-cell gene
expression, both of which cannot be ignored based on our analysis of multiple scRNA-seq
datasets (Figure 20a).
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Here we introduce a new MUlti-Subject SIngle Cell deconvolution (MuSiC) method (code
available) that utilizes cross-subject scRNA-seq to estimate cell type proportions in bulk
RNA-seq data. Through comprehensive benchmark evaluations, and applications to pan-
creatic islet and whole kidney expression data in human, mouse, and rats, we show that
MuSiC outperformed existing methods, especially for tissues with closely related cell types.
3.2. Methods
3.2.1. Method overview
An overview of MuSiC is shown in Figure 7. MuSiC starts with multi-subject scRNA-seq
data, and assumes that the cells for each subject have been classified into a set of fixed
cell types that are shared across subjects. MuSiC deconvolves bulk RNA-seq samples to
obtain the proportions of these cell types in each sample. A key concept in MuSiC is marker
gene consistency. We show that, when using scRNA-seq data as a reference for cell type
deconvolution, two fundamental types of consistency must be considered: cross-subject and
cross-cell, in which the first is to guard against bias in subject selection, and the second is to
guard against bias in cell capture in scRNA-seq. By incorporating both types of consistency,
MuSiC allows for scRNA-seq datasets to serve as effective references for independent bulk
RNA-seq datasets involving different individuals.
Rather than pre-selecting marker genes from scRNA-seq based only on mean expression,
MuSiC gives weight to each gene, allowing for the use of a larger set of genes in decon-
volution. The weighting scheme prioritizes consistent genes across subjects: up-weighing
genes with low cross-subject variance (informative genes) and down-weighing genes with
high cross-subject variance (non-informative genes). This requirement on cross-subject
consistency is critical for transferring cell type-specific gene expression information from
one dataset to another.
Solid tissues often contain closely related cell types, and correlation of gene expression
between these cell types leads to collinearity, making it difficult to resolve their relative
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Figure 7: Overview of MuSiC framework.
Music starts from scRNA-seq data from multiple subjects, classified into cell types (shown
in different colors), and constructs a hierarchical clustering tree reflecting the similarity
between cell types. Based on this tree, the user can determine the stages of recursive
estimation and which cell types to group together at each stage. MuSiC then determines
the group-consistent genes and calculates cross-subject mean (red to blue) and cross-subject
variance (black to white) for these genes in each cell type. MuSiC up-weighs genes with
low cross-subject variance and down-weighs genes with high cross-subject variance. In
the example shown, deconvolution is performed in two stages, only cluster proportions are
estimated for the first stage. Constrained by these cluster proportions, the second stage
estimates cell type proportions, illustrated by the length of the bar with different colors.
The deconvolved cell type proportions can then be compared across disease cohorts.
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proportions in bulk data. To deal with collinearity, MuSiC employs a tree-guided procedure
that recursively zooms in on closely related cell types. Briefly, we first group similar cell
types into the same cluster and estimate cluster proportions, then recursively repeat this
procedure within each cluster (Figure 7). At each recursion stage, we only use genes that
have low within-cluster variance, a.k.a. the cross-cell consistent genes. This is critical as
the mean expression estimates of genes with high variance are affected by the pervasive bias
in cell capture of scRNA-seq experiments, and thus cannot serve as reliable reference.
3.2.2. MuSiC model set-up
In this section, we derive the relation ship between gene expression in bulk tissue and cell
type-specific gene expression in single cells. This relationship forms the basis of our decon-
volution procedure. For gene g, let Xjg be the total number of mRNA molecules in subject
j of the given tissue, which is composed of K cell types. Then Xjg =
∑K
k=1
∑
c∈Ckj Xjgc,
where Xjgc is the number of mRNA molecules of gene g in cell c of subject j, and C
k
j is the
set of cell index for cell type k in subject j with mkj = |Ckj | being the total number of cells
in this set. The relative abundance of gene g in subject j for cell type k is
θkjg =
∑
c∈Ckj Xjgc∑
c∈Ckj
∑G
g′=1Xjg′c
. (3.1)
We can show that
Xjg =
K∑
k=1
mkjS
k
j θ
k
jg = mj
K∑
k=1
pkjS
k
j θ
k
jg, (3.2)
where for subject j, Skj =
∑
c∈Ck
j
∑G
g′=1Xjg′c
mkj
is the average number of total mRNA molecules
for cells of cell type k (also referred as “cell type” below), mj =
∑K
k=1m
k
j is the total
number of cells in the bulk tissue, and pkj =
mkj
mj
is the proportion of cells from cell types.
Let Yjg =
Xjg∑G
g′=1Xjg′
be the relative abundance of gene g in the bulk tissue of subject j.
Equation (3.2) implies
Yjg ∝
K∑
k=1
pkjS
k
j θ
k
jg. (3.3)
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Thus, across G genes in subject j, we have

Yj1
...
Yjg
 ∝

θ1j1 · · · θKj1
...
. . .
...
θ1jG · · · θKjg
 ·

S1j 0
. . .
0 Skj
 ·

p1j
...
pKj
 (3.4)
The goal of MuSiC is to estimate pkj using data from scRNA-seq and bulk RNA-seq.
3.2.3. Model assumptions
If scRNA-seq were available for subject j, we would be able to obtain the cell size factor Skj
(or the relative values of Skj , see below) and cell type-specific relative abundance θ
k
jg. With
bulk RNA-seq data in subject j, we get the bulk tissue relative abundance Yjg, and, if θ
k
jg
and Skj were known, we would be able to perform a regression to estimate p
k
j . However,
since scRNA-seq is still costly, most studies cannot afford the sequencing of a large number
of individuals using scRNA-seq. To make deconvolution possible for a broader range of
studies, it is desirable to utilize cell type-specific gene expression from other studies or from
a smaller set of individuals in the same study. This is feasible under the following three
assumptions:
Assumption 3.1 Individuals with scRNA-seq and bulk RNA-seq are from the same pop-
ulation, with their cell-type specific relative abundances θkjg in equation (3.1) following the
same distribution with mean θkg and variance σ
2
gk,
θkjg ∼ F (θkg , σ2gk). (3.5)
Here, F (·, ·) represents a general distributional function, which is not assumed to be of any
particular form. Under this assumption, deconvolution can use available single-cell data
from other subjects or even subjects from other studies as reference.
Assumption 3.2 The ratio of cell size Sjk across cell types are the same across subjects
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and studies:
Skj
Sk
′
j
=
Skj′
Sk
′
j′
for all subjects j, j′ ∈ {1, . . . , N} and cell types k, k′ ∈ {1, . . . ,K}. (3.6)
This second assumption allows us to replace Skj by a common value S
k across subjects. We
want to emphasize that we assume the ratio, and not the absolute value, of cell size to be
constant across subjects and studies, because to utilize the common value Sk, we need a
constant scalar in equation (3.8) as shown below.
In practice, we do not observe the actual cell sizes Skj , since (1) for non-UMI data we observe
read counts, not molecule counts and (2) for each cell we observe library size, not cell size.
Let X˜jg and X˜jgc denote the read counts for a bulk sample and for a specific cell c in the
sample, respectively. Let S˜kj =
∑
c∈Ck
j
∑G
g′=1 X˜jg′c
mkj
denote the average library size of cell type
k for subject j. We define the efficiency of cell type k for subject j as γkj = S˜
k
j /S
k
j . We
assume
Assumption 3.3 The ration of average library size is the same across cell type regardless
of subjects and studies
S˜kj
S˜k
′
j
=
S˜kj′
S˜k
′
j′
for all j, j′ ∈ {1, · · · , N} and k, k′ ∈ {1, · · · ,K}. (3.7)
Combined with assumption 3.2, equation (3.7) is equivalent to assuming that the ratio of
efficiency between cell types is conserved across subjects and studies
γkj
γk
′
j
=
γkj′
γk
′
j′
for all j, j′ ∈ {1, · · · , N} and k, k′ ∈ {1, · · · ,K}.
This assumption seems plausible, since although efficiency varies across cell types and sub-
jects, its ratio between cell types should be less variable. Assumption 3.2 and 3.3 allow
us to use the common value of library size S˜k across subjects in the read count setting.
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Assumption 3.1-3.3 enable us to recover the trend of cell type proportion change across
subjects, as shown in Section 3.3, but does not enable the recovery of absolute cell type
proportions.
To recover absolute cell type proportions, a stronger version of Assumption 3.3 is needed,
which we called
Assumption 3.4 The ratio of average library size is equal to the ratio of average cell size,
for all pairs of cell types and across all subjects and studies
S˜kj
S˜k
′
j
=
Skj
Sk
′
j
=
Skj′
Sk
′
j′
=
S˜kj′
S˜k
′
j′
for all j, j′ ∈ {1, · · · , N} and k, k′ ∈ {1, · · · ,K}.
Given Assumption 3.2 and 3.4 is equivalent to assume that the efficiency γkj is the same
across cell types, subjects and studies
γkj = γ
k′
j′ for all j, j
′ ∈ {1, · · · , N} and k, k′ ∈ {1, · · · ,K}.
This stronger assumption indicates that we can safely interchange the ratio of library size
with the ratio of cell size to estimate cell type proportion.When this assumption is not
satisfied, we can estimate the fraction of RNA molecules from each cell type, represented
by pkj × Skj , but the estimate of cell type proportion, pkj , will be biased.
3.2.4. Cell type proportion estimation
To estimate cell type proportions pj = {pkj , k = 1, · · · ,K}, we need to consider two con-
straints: (C1) Non-negativity: pkj ≥ 0 for all j, k; (C2) Sum-to-one:
∑K
k=1 p
k
j = 1 for all j.
Because the bulk tissue and single-cell relationship derived in equation (3.5) is a “propor-
tional to” relationship, to satisfy the (C2) constraint, we need a normalizing constant Cj
so that
Yjg = Cj
( K∑
k=1
pjkSkθ
k
jg + jg
)
, (3.8)
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where jg ∼ N(0, δ2jg) represents bulk tissue RNA-seq gene expression measurement noise.
When cell type proportions pj and subject-specific relative abundances θjg = {θkjg, k =
1, . . . ,K} are known, the variance of bulk tissue gene expression measurement is
Var[Yjg|pj ,θjg] = C2j δ2jg. (3.9)
Given only cell type proportions, the variance is
Var[Yjg|pj ] = E[Var[Yjg|pj ,θjg]] + Var[E[Yjg|pj ,θjg]] (3.10)
= C2j δ
2
jg + Var
[
Cj
K∑
k=1
pjkSkθ
k
jg
]
= C2j δ
2
jg + C
2
j ·
K∑
k=1
pjg
2S2kVar[θ
k
jg] = C
2
j δ
2
jg + C
2
j
K∑
k=1
p2jkS
2
kσ
2
gk
=
1
w2jg
.
Because of the heteroscedasticity of gene expression over genes, including the weight wjg
can improve estimates. Since δ2jg is unknown, we will estimate the weight wjg iteratively,
initialized by NNLS. MuSiC is robust and converges to the same value even with different
starting points (Appendix A.2.7, Figure 24).
Given that bulk and single-cell expression data are generated via different protocols, it may
also be necessary to consider gene-specific protocol bias. We note that the difference between
the grand average of the single-cell and bulk expression profiles does not necessarily reflect
bias between protocols, because the difference between cell type proportions of single-cell
and bulk expression data can also lead to expression differences of marker genes even in the
absence of protocol bias. To address potential protocol bias between bulk and single-cell
expression data, we add a gene- and subject-specific intercept in equation (3.8), that is
Yjg = Cj · (αjg +
∑K
k=1 pjkSkθ
k
jg + jg. After adjusting for the protocol bias, MuSiC can
detect significant biological signals across protocols (Figure 19, Table 6).
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MuSiC is a weighted non-negative least squares regression (W-NNLS), which does not re-
quire pre-selected marker genes. Indeed, the iterative estimation procedure automatically
imposes more weight on informative genes and less weight on non-informative genes. Be-
cause it is a linear regression-based method, genes showing less cross cell type variations will
have low leverage, thus having less influence on the regression, whereas the most influential
genes are those with high weight and high leverage. To illustrate this point, we also per-
formed benchmarking experiments to show that applying MuSiC using all genes gives more
accurate results than applying MuSiC using pre-selected marker genes, thus demonstrating
that MuSiCs weighting scheme makes marker gene pre-selection unnecessary (Figure 20c,
Figure 21). MuSiC can also deal with batch effect with its weighting scheme. When batch
effect is present, the variance of relative abundance will generally increase for all cell types.
This means that the batch effect with be absorbed in σkg, meaning that MuSiC not only
up-weighs cross-subject consistent genes, but also cross-batch consistent genes. Thus, by
down-weighting cross-batch variable genes, MuSiC effectively deals with batch effects.
The weighting scheme in MuSiC enables automatic selection of marker genes for deconvo-
lution, as supported by our findings from the pancreas and kidney data (marker genes are
highlighted with colors in Tables 11-13). However, we note that some of the top-ranked
genes are not necessarily marker genes. This is because genes in MuSiC are weighed by
the combined effect of cross-subject variation and cross-cell-type variation, which are very
different concepts. The cross-subject variation measures the consistency of genes across
subjects while the cross-cell-type variation measures the cell type specificity of genes. The
top ranked non-markers genes for the analyses in Results tend to be consistently expressed
across subjects, and are usually highly expressed. Although they are not exclusively ex-
pressed in a particular cell type, they are differentially expressed across cell types, thus
offering power to differentiate different cell types. We believe that MuSiC benefit from
these genes and hence yield more accurate cell type proportions than methods that only
use marker genes in deconvolution.
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3.2.5. Recursive tree-guided deconvolution for closely related cell types
Complex solid tissues often include closely related cell types with similar gene expression
levels. Correlation in gene expression can lead to collinearity, making it difficult to reliably
estimate cell type proportions, especially for less frequent and rare cell types. Although
the collinearity problem can be improved by selecting marker genes through support vector
regression, as is done in CIBERSORT[ref3] and BSEQ-sc[ref4], these approaches still have
limited power to resolve similar cell types. In MuSiC, we introduce a recursive tree-guided
deconvolution procedure based on a cell type similarity tree, which can be easily obtained
through hierarchical clustering. In stage 1 of this procedure, cell types in the design matrix
are divided into high-level clusters by hierarchical clustering with closely related cell types
clustered together. Proportion for these cell type clusters are estimated using genes with
small intra-cluster variance (cluster-consistent genes) using the above described W-NNLS.
In stage 2, for cell types in each cluster, the cell type proportions are estimated using
W-NNLS with genes displaying small intra-cell type variance, subject to the constraint on
the pre-estimated cluster proportions. If necessary, more than 2 stages of recursion can
be applied, with each stage separating the cell types within each large cluster into finer
clusters, and using cluster-consistent genes to do W-NNLS subject to the constraint that
fixes higher-level cluster proportions.
To illustrate this recursive tree-guided deconvolution procedure, we start with a simple case
with four cell types and G genes. Let X1,X2,X3,X4 represent cell type-specific expression
in the design matrix, obtained from scRNA-seq, and let Y be the gene expression vector in
the bulk RNA-seq data. The relationship of bulk and single-cell data can be written as
Y (1)
Y (2)
 =
X(1)1 X(1)2 X(1)3 X(1)4
X
(2)
1 X
(2)
2 X
(2)
3 X
(2)
4


p1
p2
p3
p4

+
 (1)
(1),
 (3.11)
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where the superscripts (1) and (2) indicate two sets of genes. Suppose the four cell types are
grouped into two clusters, (X1, X2) and (X3, X4). The first set of genes are those showing
small intra-cluster variance in gene expression, that is, X
(1)
1 ≈ X(1)2 and X(1)3 ≈ X(1)4 ,
whereas the second set of genes are the remaining genes.
Stage 1 Estimate cluster proportions pi1 = p1 + p2 and pi2 = p3 + p4,
Y (1) = X
(1)
1 pi1 +X
(1)
3 pi2 + 
(1). (3.12)
The cluster proportions, pˆi1 and pˆi2, are estimated by W-NNLS using intra-cluster
homogenous genes.
Stage 2 : Estimate cell type proportions (p1, p2, p3, p4),
Y (2) = X
(2)
1 p1 +X
(2)
2 p2 +X
(2)
3 p3 +X
(2)
4 p4 + 
(2). (3.13)
The cell type proportions are estimated by W-NNLS using the remaining genes subject
the constraint that
pˆ1 + pˆ2 = pˆi1, and pˆ3 + pˆ4 = pˆi2. (3.14)
3.2.6. Interconversion of different gene expression measures
MuSiC links bulk and single-cell gene expression by mRNA molecule counts. There are
many measures of mRNA abundance, such as read counts, UMI counts, RPKM and TPM.
As molecule counts are not observed in real studies, we approximate the molecule counts
by read counts and estimate cell type proportions based on assumptions 3.1 - 3.3. The
interconversion between other gene expression measures and read count determines if MuSiC
can utilize other measures as the input for deconvolution. One step in MuSiC estimation is
the use of average library size as a proportional measure of average cell size for a given cell
type, which is absent in normalized measurements of mRNA abundance such as RPKM and
TPM. For RPKM, we would need the average library size for each cell type to be provided,
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or the average cell size for each cell type to be obtained from other sources. Cell type
proportions cannot be estimated by MuSiC with TPM information alone. Below, we derive
the relationships of various types of gene expression measures in detail.
Let Lg denote the length of gene g, and the corresponding RPKMs of bulk and single-cell
data are denoted by Xˆjg and Xˆjgc, respectively. For simplicity, we omit the 10
3 scalar for
now. By definition,
Xˆjg =
X˜jg/Lg∑G
g′=1 X˜jg′
, X˜jgc =
X˜jgc/Lg∑G
g′=1 X˜jg′c
, (3.15)
where X˜jg and X˜jgc denote the bulk and single cell read counts, respectively.
Based on the model set-up described earlier, we can show that the relationship between
bulk and single-cell RPKMs is
Xˆjg ∝ X˜jg
Lg
=
K∑
k=1
∑
c∈Ckj
( X˜jgc/Lg∑G
g′=1 X˜jg′c
·
G∑
g′=1
X˜jg′c
)
=
K∑
k=1
∑
c∈Ckj
XˆjgcS˜jc (3.16)
where S˜jc is the library size of cell c. Equation (3.16) can be further approximated by
Xˆjg ∝
K∑
k=1
∑
c∈Ckj
XˆjgcS˜jc ≈
K∑
k=1
mkj θˆ
k
jgS˜
k
j = mj
K∑
k=1
pkj θˆ
k
jgS˜
k
j (3.17)
where θˆkjg =
∑
c∈Ckj Xˆjgc/m
k
j is the average RPKM of gene g in subject j for cell type k.
To utilize multi-subject information, we assume θˆkjg follows the same assumption as As-
sumption 3.1, that is, individuals with scRNA-seq and bulk RNA-seq are from the same
population, with their cell-type specific average RPKM θˆkjg following the same distribution
with mean θˆkg and variance σˆ
2
gk,
θˆkjg ∼ F˜ (θˆkg , σˆ2jg). (3.18)
Assumption 3.2 states that the ratio of average library size is consistent across subjects and
studies, which justifies the use of S˜kj from other studies if these quantities are not available
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for the same data set. The linear relation between bulk RPKM and average cell-type specific
single cell RPKM is approximated by formula (3.17). Since this is an approximation, MuSiC
estimates using RPKM may not be as accurate as those using read or UMI count. In our
test of MuSiC using RPKM values for the pancreatic islets bulk mixture experiment, we
found that it is not as accurate as MuSiC estimates using read count, but still higher than
NNLS, BSEQ-sc, and CIBERSORT (Figure 23d).
Another widely used normalized mRNA measure is TPM. Let Zˆjg and Zˆjgc denote the
bulk and single-cells TPM values, respectively. By definition, . Let Zjg and Zjgc be the
gene length normalized read count in bulk and single cell, that is, Zjg = X˜jg/Lg and
Zjgc = X˜jgc/Lg. The link between bulk and single-cell TPMs is
Zˆjg ∝ Zjg =
K∑
k=1
∑
c∈Ckj
Zjgc =
K∑
k=1
∑
c∈Ckj
( Zjgc∑G
g′=1 Zjg′c
·
G∑
g′=1
Zjg′c
)
=
K∑
k=1
∑
c∈Ckj
ZˆjgcSˆjc, (3.19)
where Sˆjc is the summation of normalized read counts in cell c for subject j. Equation
(3.19) suggests that it is difficult to make assumptions or approximations to express relative
abundance as a function of TPM.
3.2.7. Construction of benchmark datasets and evaluation metrics
To evaluate MuSiC and compare with other deconvolution methods, we need bulk RNA-
seq data with known cell type proportions. Therefore, we construct artificial bulk tissue
data from a scRNA-seq dataset in which the bulk data is obtained by summing up gene
counts from all cells in the same subject. Relative abundance is calculated by equation
(3.1). The true cell type proportions in the artificial bulk data can be directly obtained
from the scRNA-seq data and this allows us to use this artificially constructed bulk data
as a benchmark dataset to evaluate the performance of different deconvolution methods
(A.2.2). Denote the true cell type proportions by p and the estimated proportions by pˆ.
Deconvolution methods are evaluated by the following metrics.
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(i) Pearson correlation, R = Cor[p, pˆ];
(ii) Root mean squared deviation, RMSD =
√
avg(p− pˆ)2;
(iii) Mean absolute deviation, mAD = avg(|p− pˆ|).
3.3. Results of deconvolution
3.3.1. Application to pancreatic islets in human
To demonstrate and evaluate MuSiC, we started with a well-studied tissue, the islets of
Langerhans, which are clusters of endocrine cells within the pancreas that are essential for
blood glucose homeostasis. Pancreatic islets contain five endocrine cell types (α, β, δ, , and
γ), of which β cells, which secrete insulin, are gradually lost during type 2 diabetes (T2D).
We applied MuSiC to bulk pancreatic islet RNA-seq samples from 89 donors from Fadista
et al. (2014), to estimate cell type proportions and to characterize their associations with
hemoglobin A1c (HbA1c) level, an important biomarker for T2D. We were motivated to re-
analyze this data because, as shown in Figure 8 and in Baron et al. (2016), existing methods
failed to recover the correct β cell proportions, which should be around 50-60%, and also
failed to recover their expected negative relationship with HbA1c level. As reference, we
experimented with scRNA-seq data from two sources: 6 healthy and 4 T2D adult donors
from Segerstolpe et al. (2016), and 12 healthy and 6 T2D adult donors from Xin et al.
(2016). All bulk and single-cell datasets in this analysis are summarized in Table 1.
First, to systematically benchmark, we applied MuSiC and three other methods (Non-
negative least squares (NNLS), CIBERSORT, and BSEQ-sc) to artificial bulk RNA-seq data
constructed by simply summing the scRNA-seq read counts across cells for each single-cell
sequenced subject. In this case, true cell type proportions are known, which allows the
evaluation of accuracy. More details on artificial bulk construction are described in the
Appendix A.2.2. Figure 8a, 20c and Figure 21b show the estimation results when the
artificial bulk and the single-cell reference data are from the same study, either both from
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Figure 8: Pancreatic islet cell type composition in healthy and T2D human samples.
a and b Benchmarking of deconvolution accuracy on bulk data constructed by combin-
ing together scRNA-seq samples. a. The bulk data is constructed for 10 subjects from
Segerstolpe et al. (2016) while the single cell reference is taken from the same dataset. The
cell type proportions of healthy subjects are estimated by leave-one-out single cell refer-
ence. The subject names are relabeled; the table shows average root mean square error
(RMSD), mean absolute deviation (mAD), and Pearson correlation (R) across all samples
and cell types. b. The bulk data is constructed for 18 subjects from Xin et al. (2016)
while the single cell reference is 6 healthy subjects from Segerstolpe et al. (2016). c. Jitter
plots of estimated cell type proportions for Fadista et al. (2014) subjects, color-coded by
deconvolution method. Of the 89 subjects from Fadista et al. (2014), only the 77 that
have recorded HbA1c level are plotted, and T2D subjects are denoted as triangles while
non-diabetic subjects are denoted as dots. d. HbA1c vs beta cell type proportions esti-
mated by each of 4 methods. The reported p-values are from single variable regression β
cell proportion HbA1c. Multivariable regression results are reported in Table 6. Figure 19
shows the deconvolution results of Fadista et al. (2014) with the inDrop data from Baron
et al. (2016) as single-cell reference. The corresponding multivariable regression results are
shown in Table 6.
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Name
Accession
number
Data type Protocol # sample # cells # genes
Segerstolpe
et al. (2016)
E-MTAB-
5061
Single cell
Smart-
seq2
10 (6H +
4 T2D)
2209 25453
Segerstolpe
et al. (2016)
E-MTAB-
5060
Single cell
Smart-
seq2
7 (3H + 4
T2D)
NA 25453
Xin et al.
(2016)
GSE81608 Bulk
18 (12H +
6 T2D)
1492 39849
Baron et al.
(2016)
GSE81433 Single cell InDrop 3H 7729 17434
Fadista
et al.
(2014)
GSE50244 Bulk 89 NA 56638
Table 1: Pancreatic islet datasets
For data type column, “Single cell” means “single cell RNA-seq” and “Bulk” represents
“bulk RNA-seq”. For # sample column, “H” means “healthy” and “T2D” means “type 2
diabetes”.
Segerstolpe et al. (2016) or both from Xin et al. (2016). MuSiC achieves improved accuracy
over existing procedures. Figure 8b and Figure 21a show the estimation results when the
artificial bulk and the single-cell reference data are from different studies. This is a more
challenging but more realistic scenario, since library preparation protocols vary across labs
and bulk deconvolution analyses are often performed using single-cell reference generated
by others. MuSiC still maintains high accuracy, while other methods perform substantially
worse. Further comparisons show that, unlike existing methods that rely on pre-selected
marker genes, MuSiC gives accurate results when the cell type composition in the bulk data
is substantially different from that of the single cell reference (Figure 21c and Appendix
A.2.3), and when the bulk tissue contains minority cell types that are missing in the reference
(Figure 22 and Appendix A.2.4). MuSiCs ability to transfer knowledge across data sources
is derived from its consideration of marker gene consistency.
We now turn to the deconvolution of bulk RNA-seq data from Fadista et al. (2014). We
first used the scRNA-seq data from Segerstolpe et al. (2016) as reference for all methods.
MuSiC recovers the expected ≈ 50− 60% β cell proportion for the healthy subjects (Cabr-
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era et al., 2006), whereas other methods grossly overestimate the proportion of α cells and
underestimate the proportion of β cells. Furthermore, MuSiC detects a significant asso-
ciation of β cell proportion with HbA1c level (p-value = 0.00126, Figure 8d). Based on
clinical standard, HbA1c level < 6.0% is classified as normal, and > 6.5% is classified as
diabetic. After adjusting for age, gender and body mass index, MuSiC estimates suggest
that a 0.5% increase in HbA1c level, representing the magnitude of increase from normal
to the diabetes cutoff, corresponds to a drop of 3.07%± 2.49% in β cell proportion (Table
5). The scRNA-seq data from Segerstolpe et al. (2016) was generated by the Smart-seq2
protocol. Similar results are obtained when using the InDrop scRNA-seq data from Baron
et al. (2016) as reference. MuSiC detects the significant association of β cell proportion
with HbA1c level with and without adjustment for covariates (Figure 19, Table 6). The
weight ordered gene list for pancreatic islet analysis are provided in Table 11.
3.3.2. Application to kidney in mouse and rats
As a second tissue example, we used the kidney, a complex organ consisting of several
anatomically distinct segments each playing critical roles in the filtration and re-absorption
of electrolytes and small molecules of the blood. Chronic kidney disease (CKD), the gradual
loss of kidney function, is increasingly recognized as a major health problem, affecting 10-
16% of the global adult population. We aim to characterize how kidney cell type composition
changes during CKD. Fibrosis is the histologic hallmark common to all CKD models, and
hence, we analyzed the bulk RNA-seq data from three mouse models for renal fibrosis:
unilateral ureteric obstruction induced by surgical ligation of the ureter (UUO, Arvaniti
et al. (2016)), toxic precipitation in the tubules induced by high dose folic acid injection (FA,
Craciun et al. (2016)), or genetic alteration by transgenic expression of genetic risk variant
APOL1 in podocytes (APOL1 transgenic mice12). As reference, we used the mouse kidney
specific scRNA-seq data from Park et al. (2018). Details of all datasets are summarized
in Table 2. We systematically benchmarked all methods on artificial bulk experiments
performed using the Park et al. (2018) scRNA-seq data, finding similar trends as those in
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Figure 8a-b (Figure 25a-b).
Name
Accession
number
Data type Protocol # sample
#
cells
#
genes
Park et al.
(2018)
GSE107585 Single cell 10x 7H 43745 16273
Beckerman
et al. (2017)
GSE81492 Bulk
10 (6 control +
4 APOL1 )
NA 19033
Lee et al.
(2015)
GSE56743 Bulk
118 replicates
(14 segments)
NA 10903
Craciun
et al.
(2016)
GSE65267 Bulk
18 replicates (6
time points)
NA 25219
Arvaniti
et al.
(2016)
GSE79443 Bulk
10 replicates
(Sham + 2
time points)
NA 38683
Table 2: Mouse/Rat kidney datasets
For data type column, “Single cell” means “single cell RNA-seq” and “Bulk” represents
“bulk RNA-seq”. For # sample column, “H” means “healthy” and “T2D” means “type 2
diabetes”.
Hierarchical clustering of the cell types in the single cell reference reveals that, apart from
neutrophils and podocytes, kidney cells fall into two large groups: Immune cell types
(macrophages, fibroblasts, T lymphocytes, B lymphocytes, and natural killer cells) and
kidney-specific cell types (proximal tubule, distal convolved tubule, loop of Henle, two cell
types forming the collecting ducts, and endothelial cells). Of these, proximal tubule (PT)
is the dominant cell type in kidney, and the proportion of PT cells is known to decrease
with CKD progression. MuSiC finds this decrease in all three mouse models (Figure 9b-d).
Other methods also detect this association for the APOL1 and UUO mouse models, but
showed ambiguous results for the FA model.
Distal convolved tubule cells (DCT) are known to be the second most numerous cell type in
kidney, with an expected proportion of 10-20%. Yet, CIBERSORT did not detect DCT in
any of the three bulk datasets; BSEQ-sc missed it in two datasets and grossly over-estimated
its proportion in the third dataset at the cost of a grossly underestimated PT proportion.
This is due to the high similarity between DCT and PT, observable in Figure 9a. Through
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Figure 9: Cell type composition in kidney of mouse CKD models and rat.
a. Cluster dendrogram showing similarity between 13 cell types that were confidently
characterized in Park et al. (2018). Abbreviations: Neutro: neutrophils, Podo: podocytes,
Endo: endothelials, LOH: loop of Henle, DCT: distal convolved tubule, PT: proximal tubule,
CD-PT: collecting duct principal cell, CD-IC: CD intercalated cell, Macro: macrophages,
Fib: fibroblasts, NK: natural killers. b, c and d. Average estimated proportions for 6 cell
types in bulk RNA-seq samples taken from 3 different studies, each study based on a different
mouse model for chronic kidney disease. Results from three different deconvolution methods
(MuSiC, BSEQ-sc and CIBERSORT) are shown by different colors. Supplementary Figure
27a-c show complete estimation results of all 13 cell types. b. Bulk samples are from
Beckerman et al. (2017), who sequenced 6 control and 4 APOL1 mice. c. Bulk data
are from Craciun et al. (2016), where samples are taken before (C) and at 1, 2, 3, 7, 14
days after administering folic acid. Line plot shows cell type proportion changes over time
(days), averaged over 3 replicates at each time point. d. Bulk data are from Beckerman
et al. (2017), where samples are taken from mice after Sham operation (C), 2 days after UUO
operation (D2), and 8 days after UUO operation (D8). The average proportions at each time
point are plotted. e. MuSiC estimated cell type proportions of rat renal tubule segments.
The estimated cell type proportions (left) and the proportions correlations between samples
(right) are shown as heatmap. Segment names are color coded and aligned according to
their physical positions along the renal tubule. Figure 26a-c show NNLS, BSEQ-sc and
CIBERSORT results. See Table 10 for full segment names.
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its tree-guided recursive algorithm, MuSiC first estimates the combined proportion of kidney
cell types versus immune cell types using consistent genes for these two large groups, and
then zooms in and deconvolves the kidney cell types using genes re-selected for each kidney
cell type. This allows MuSiC to successfully separate PT and DCT cells in all three bulk
datasets, recovering a consistent DCT proportion between 8-20%, matching expectations.
Interestingly, unlike for PT, the proportion of DCT cells show a consistent increase with
disease progression across all three mouse models. This may seem counter-intuitive given
that loss of kidney function is expected to be associated with the loss of kidney cell types.
But given the substantial drop of the dominant PT cell type, the proportion of DCT cells
relative to the whole may increase, even if its absolute count drops.
Next, we consider immune cells, which are known to play a central role in the pathogenesis
of CKD. MuSiC found the largest immune sub-type to be macrophage, and all methods
detected the expected increase of macrophage proportion with disease progression. Apart
from this, MuSiC also found fibroblasts, B-, and T-lymphocytes to increase in proportion
with disease progression, giving a consistent immune signature that is reproduced across
mouse models. These findings are consistent with clinical and histological observations,
indicating tissue inflammation is a consistent feature of kidney fibrosis. Such reproducible
signatures were not found by other methods, which show much less agreement across mouse
models. The weight ordered gene list for the three mouse models are provided in Table
12-13.
Finally, to illustrate MuSiCs cross-species applicability, we used the mouse kidney scRNA-
seq reference from Park et al. (2018) to deconvolve the micro-dissected segment aggregated
rat RNA-seq data from Lee et al. (2015), which contains 105 samples obtained from 14
segments spaced along the renal tubule. Cell type proportions are estimated with homol-
ogous genes between mice and rat. We mapped samples to their physical locations, and
computed correlations between their cell type proportions (Figure 9). Reassuringly, cell
types recovered by MuSiC for each segment agree with knowledge (Zhai et al., 2006) about
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the dominant cell type at its mapped position, e.g. DCT cells come from the DCT segment.
Correlation between samples is also high within anatomically distinct segments.
3.3.3. Evaluation of robustness for MuSiC
A good deconvolution method should be robust to the choice of single-cell reference. We
conducted additional experiments to evaluate the robustness of MuSiC and other existing
methods. First, we considered the case where cell type proportions in the single cell data
are drastically different from those in the bulk data. Our results indicate that, under
this scenario, MuSiC recovers the true cell type composition, improving upon the severely
biased estimates produced by other existing approaches (Appendix A.2.3, Figure 21c). One
limitation of scRNA-seq is that it may fail to recover some cell types, in particular, rare cell
types may be missed. We next created considered the setting where the single-cell reference
is incomplete, and found that MuSiC estimation is still accurate as long as the missing cell
type is not the dominant cell type in bulk tissue (Appendix A.2.4, Figure 22, and Table
7). MuSiC is also tolerant of different scRNA-seq protocols. This has already been shown
through the above analyses, where accurate deconvolution results were obtained using single
cell reference generated using the Smart-seq2, inDrop, and 10x Chromium protocols. To
probe this further, we directly investigated the impact of using biased values of relative
abundance θkjg in MuSiCs deconvolution step, and found that MuSiC estimated cell type
proportions remain accurate, still improving upon existing methods, even though unbiased
relative abundance values were provided to the existing methods as input (Appendix A.2.5,
Figure 23c). Finally, we evaluated the impact of dropout in the single cell reference, by
introducing dropout according to Jia et al. (2017) and varying the dropout rate in the
benchmark experiment of Figure 8. MuSiC estimation is still accurate even when dropout
rate is around 30% (Appendix A.2.6, Figure 23a-b).
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3.4. Discussion
Knowledge of cell type composition in disease relevant tissues is an important step towards
the identification of cellular targets in disease. Although most scRNA-seq data do not
reflect true cell type proportions in intact tissues, they do provide valuable information on
cell type-specific gene expression. Existing cell type deconvolution methods rely on pre-
selected marker genes and ignore subject-to-subject variation and cross-cell consistency in
gene expression. Through comprehensive benchmark evaluations and analysis of multiple
real datasets, we show that both cross-subject and cross-cell consistency in gene expression
need to be considered in deconvolution. By incorporating both types of consistency, MuSiC
allows for scRNA-seq datasets to serve as effective references for independent bulk RNA-
seq datasets involving different individuals. Harnessing multi-subject scRNA-seq reference
data, MuSiC reliably estimates cell type proportions from bulk RNA-seq, therefore enabling
the transfer of cell type-specific gene expression from one dataset to another. As bulk tissue
data are more easily accessible than scRNA-seq, MuSiC allows the utilization of the vast
amounts of disease relevant bulk tissue RNA-seq data for elucidating cell type contributions
in disease.
Although this paper uses read counts as the measures of mRNA abundance, there are many
other commonly used measures, such as RPKM and TPM. MuSiC can utilize RPKM if
estimates of cell type specific total RNA abundance can be provided (e.g. estimated from
another data set). However, cell type proportions cannot be estimated with TPM as the
input. Detailed interconversion between read counts and other gene expression measures
have been discussed in Section 3.2.
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CHAPTER 4 : Cell type specific differential expression from bulk tissue with single
cell reference
4.1. Introduction
In Chapter 3, we developed a deconvolution method, MuSiC, which estimates bulk tissue
cell type proportions with single cell reference without requiring the pre-selection of marker
gene. The real data examples in Section 3.3 confirmed the heterogeneity of cell type pro-
portions across subjects and conditions. In the pancreas islet analysis, beta cell proportions
associated negatively with HbA1c level, which is an indicator of diabetes. In this chapter,
we examined how these estimated proportions can be used to more detailed characterize of
gene expression changes across biological conditions.
Differential expression analysis is one of the common tools for discovering quantitative
changes in expression levels between biological conditions, by testing if the difference of
expression levels between biological conditions is greater than that due to natural random
variations. Methods for differential expression analysis with bulk RNA-seq data have been
developed. Currently, popular ones include DESeq2(Love et al., 2014), edgeR(Robinson
and Oshlack, 2010), and more in Costa-Silva et al. (2017). However, differential expression
analysis using bulk RNA-seq data is a product of the cell-type specific contribution and
the cell type proportion changes, which is inadequate for cell type level study. With help
of single cell reference, we are now able to quantify, using MuSiC, cell type proportions
but the cell type specific differential expression are still unclear to us. Although, scRNA-
seq make it possible to compare the cell type specific expression between conditions, the
cost and labor usually limit the application of scRNA-seq. With cell type proportions, the
large quantities to large cohorts of bulk sequencing data is still useful for cell-type specific
differential expression analysis.
As stated in Chapter 3, bulk sequencing data and cell type proportions of the same tissue
usually can not be observed at the same time. Hence, deconvolution is needed before
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cell-type-specific differential expression analysis, for estimating the cell type proportions
of the same tissue. Deconvolution methods such as CIBERSORT(Newman et al., 2015)
and BSEQ-sc(Baron et al., 2016), as we mentioned in Chapter 3, pre-select marker genes.
Deconvolution methods with marker genes assume that the expression of marker genes are
consistent across conditions, which is not always true consider, for example, beta cell in
the pancreas, whose main role is the production of insulin. INS is the gene responsible
for insulin production and has always considered as a marker gene for beta cells. During
the progression of type 2 diabetes, beta cells representation in the pancreas, decrease in
number, but within the beta cells that are retained, there is also a functional decline (Porte
and Kahn, 2001), where the expression of INS is lower in diseased subjects than healthy
subjects. Although the expression of INS can still be used as marker genes for beta cell in
diseased subjects, using only INS as the marker gene for deconvolution will attribute all of
the differential expression to cell type proportions changes, while some of it is due to within
cell type expression shift.
To avoid the biases of estimated proportions introduced by marker genes, we use MuSiC
for deconvolution without marker genes. When incorporating both diseased and healthy
single cell profile, we can automatically up-weigh genes that have consistent expression
across different cohorts by MuSiC. However, using all genes for proportion estimation would
confound the results of differential expression tests, where the estimated cell type specific
gene expressions from both cohorts are driven towards the expression from single cell profile.
Here we developed a method, MuSiC-DE, for finding cell type specific differential expressed
(DE) gene from bulk data and single cell reference. We first estimate cell type proportions
using a subsample of genes and then test differential expression on the rest of the genes,
conditioning on the estimated cell type proportions. Repeating the subsampling-testing
procedure multiple times, each gene in the bulk expression data is tested at least one time
and gets a least one p-value. Since the p-values across repetitions are correlated, we apply
the empirical Bayes framework to the p-values and determine the DE genes.
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In this chapter, we focus on testing cell type specific differential expression with examples
of human pancreas islet. This chapter is organized as follows: Section 4.2.1 introduced the
null hypothesis and notations for DE test. In Section 4.2, we described the MuSiC-DE
model, detailed estimation procedures and expected results. Null distribution validation
using Fadista et al. (2014) data, benchmark examination with Xin et al. (2016), and the
DE test results of Fadista et al. (2014) are shown in Section 4.3. We summarized methods
and results and discussed future directions in Section 4.4.
4.2. Method
4.2.1. Model Set-up and Notations
We consider, for simplicity, the two-group scenario. Our method and analysis can be easily
extended to multiple-group scenarios.
Suppose there are subjects j = 1, . . . , N , gene g = 1, . . . , G and cell types k = 1, . . . ,K.
For each subject sequenced by bulk RNA-seq, we have an indicator of whether the subject
is healthy or diseased, tj :
tj =

1 disease
0 normal
For subject j and cell type k, the cell type proportions are denoted by pjk.
For subject j and gene g, bulk expression can be view as weighted sum of cell type specific
expression βkg, where the weights are cell type proportions pjk. There are some rare cell
types not presenting in the single cell profile and the intercepts are required to incorporate
the expression of those rare cell types. We assume that bulk expression, denoted as Xjg
follows a linear additive model
Xjg = β0g +
∑
k=1
pjkβkg + α0gtj +
∑
k
pjktjαkg + jg. (4.1)
We called model (4.1) full model. There are two different interpretation of this model,
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depending on the data what we input for Xjg. In the first case, Xjg is the normalized read
counts, counts per million (CPM). Correspondingly, β0g is the mean of missing cell types’
expression and βkg is the cell type specific expression for cell type k. The cell type specific
differences between diseased and healthy subjects are modeled by αkg. jg, the noise term,
does not follow normal distribution in general. In the second case, Xjg = log(CPM + 1)
is log-transformed CPM and the interpretation above no longer holds. βkg is the cell type
specific parameters, instead of cell type specific gene expression. The cell type specific
difference between diseased and healthy subjects are modeled by αkg. In this case, it is
more reasonable to assume that the noise term jg normal homoscedasticity.
Now, under the context of this model (4.1), our goal is to detect cell type specific differential
expression for each gene. The cell type proportions are not known in general, but can be
estimated by deconvolution. In our derivation of test statistics, we will assume the scenario
where proportions(pjk) are known and then treat the case where it is unknown.
When the cell type proportions pjk are known, the differential expression analysis can be
reduced into two hypothesis testing problems. The first hypothesis is
H01 : αkg = 0 for all k ∈ {0, 1, . . . ,K}. (4.2)
Testing H01 is equivalent to testing that after accounting for proportions difference, which
gene (genes) are still differential expressed across all of the cell types. For genes that reject
H01, we further specify in which cell type those genes differential expressed by testing the
second hypothesis
H
(k)
02 : αkg = 0 for a certain k ∈ {0, 1, . . . ,K}. (4.3)
Cell type proportions can be estimated by deconvolution methods with proper single cell
reference. With estimated cell type proportions, pˆjk, we can run regression of equation (4.1)
and estimate β0g, βkg, α0g and αkg at the same time. We call the regression that estimates
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cell type specific expression with known cell type proportions as “Reverse regression”. To
test H01 and H02, we compared equation (4.1) with regression under null hypothesis:
Xjg = β0g +
∑
k=1
pjkβkg + jg. (4.4)
When treating Xjg as CPM and βkg as cell type specific expression, we can not estimate
cell type specific expression by ordinary least square due to the non-negative constraints on
cell type specific expression, that is, βkg ≥ 0 and βkg + αkg ≥ 0 for all k ∈ {0, 1, . . . ,K}.
Therefore, the null hypothesis H01 can not be tested by ANOVA test by comparing the
residual of the full model (4.1) and cell type model (4.4). Through the literature, there are
no test statistics for constrained linear regression. If we view Xjg as log-transformed CPM
and βkg as cell type specific parameters, full model (4.1) and cell type model (4.4) satisfy
the requirement for ordinary least square estimation and H01 can be tested by ANOVA test.
In this chapter, we examined both interpretations and found out the second interpretation,
taking Xjg as log-transformed CPM, performs better in null distribution validation.
4.2.2. Hypothesis testing procedures
The reverse estimation and the hypothesis tests can be easily done when true cell type
proportions of bulk tissues are available. However, this is usually not the case and we need
to substituted with estimated cell type proportions from deconvolution methods. Using
marker gene based deconvolution methods may bias cell type proportion estimates, which
would lead to inaccurate cell type specific expression estimates from reverse regression.
MuSiC can avoid bias from marker genes selection by assigning weights to all genes. The
weights are calculated by the inverse of cross-subject variance and genes differential ex-
pressed across different conditions will receive low weights. However, there still exists a
confounding problem in the reverse regression when a gene is tested and is used to estimate
proportions at the same time. To tackle the confounding problem, we randomly partition
common genes of bulk data and single cell data into two sets, deconvolution set and DE
test set. Genes in DE test set are tested using proportions estimated with genes in the
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deconvolution set. We repeat the partition-test steps many times so that all common genes
get tested. Detailed procedures are described in Algorithm 4.2.2 and we call our method:
MuSiC-DE. [H]
Matrix of bulk expression X = (Xjg); Number of bulk subjects N ; Number of common
genes between bulk data and single cell data G; Number of cell types K; Repetition times R;
size of deconvolution setm P-values p = (p(g)) for all repetitions and genes Initialization:
r = 1; List p = (p(g)) of length G r ≤ R Randomly select m genes from G common genes
Estimate cell type proportions by MuSiC with selected m genes, estimated proportions are
qˆjk Test H01 by comparing model (4.1) and model (4.4) with qˆjk for each of the left-over
(G−m) genes Get p-values for each left-over genes: p(g)r r = r + 1;
In a given repetition, a gene receives the p-value if it was not selected for deconvolution.
Suppose there are Rg p-values for gene g, that is, Rg out of R repetitions do not select gene
g for deconvolution. If the null hypothesis H01 is true, the p-values should be distributed
uniformly on [0, 1]. However, the p-values across repetitions of a given are correlated. Next,
we are going to model the correlation with z-values transformed from p-values under the
null distribution.
4.2.3. Null distribution validation
Null distribution validation focuses on the healthy subjects in real bulk datasets where there
are no true cell type specific differential expression for all genes. By randomly assigning
pseudo-labels to the healthy subjects, we split them into two groups, whose gene expressions
are of the same distribution. In this scenario, the null hypothesis H01 holds.
If the p-values derived from test statistics are accurate, we are expected to see the p-values
follow the uniform distribution on [0, 1].
In previous section, we introduced two models (equation (4.1) and (4.4)) and tested the
null hypothesis by comparing them. Suppose there are L different random labelings and R
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repetitions of partition-test procedure to get p-values and gene g receives L×Rg p-values.
Let p
(g)
l,r denote the p-value from lth label and rth repetition for g genes and z
(g)
l,r denote the
z-value transformed from p-value. Under the null hypothesis, the z-values should follow a
standard normal distribution.
p
(g)
1,1 · · · p(g)1,Rg
...
. . .
...
p
(g)
L,1 · · · p(g)L,Rg
 −→

z
(g)
1,1 · · · z(g)1,Rg
...
. . .
...
z
(g)
L,1 · · · z(g)L,Rg
 (4.5)
Under the null, the z-values for gene g and random labeling l follows a multivariate normal
distribution. However, as we stated before, the z-values from each repetition are correlated
with each other with correlation ρg. This is due to the correlated estimated cell type pro-
portions across repetitions, which are generated by overlapped deconvolution genes across
repetitions. The mean and variance of z-values are denoted as µg = 0 and σ
2
g = 1, respec-
tively. The distribution for z-values (z
(g)
l,1 , . . . , z
(g)
l,Rg
)T are shown in equation (4.6) below.

z
(g)
l,1
...
z
(g)
l,Rg
 ∼ N(µg1, σ2g

1 · · · ρg
. . .
ρg · · · 1
). (4.6)
Since we randomly assigning the labels for validation, the distribution of z-values across
labelings are identical and independent.
For labeling l, The average across repetitions, denoted as z¯
(g)
l , follows a normal distribution:
z¯
(g)
l ∼ N(µg,
1 + (Rg − 1)ρg
Rg
σ2g), i.i.d. (4.7)
and the variance across labeling is
Var.l = Var[z¯
(g)
l ] =
1 + (Rg − 1)ρg
Rg
σ2g . (4.8)
56
The empirical variance across repetition z
(g)
l,1 , . . . , z
(g)
l,Rg
is
Var.r = E[
1
Rg
Rg∑
r=1
(z
(g)
l,r − z¯(g)l )2] =
Rg − 1
Rg
(1− ρg)σ2g . (4.9)
We can identify ρg and σ
2
g from cross labeling variance and cross repetition variance.
σˆ2g = Var.r + Var.l (4.10)
ρˆg = 1− Rg ·Var.r
(Rg − 1)σˆ2g
(4.11)
The mean of z-values, µg, can be estimated from null distribution validation by the average
across z¯
(g)
l , denoted as z¯
(g).
4.2.4. Differential expressed genes selection
The analysis with real labels only provides Rg p-values for gene g. If gene g is not differential
expression in all cell types, the distribution is the same as (4.6) with µg = 0 and σg = 1.
The test statistics are
z¯(g) =
1
Rg
Rg∑
r=1
z(g)r ∼ N(0,
1 + (Rg − 1)ρg
Rg
) (4.12)
and
Sg =
1
Rg
Rg∑
r=1
(zr − z¯(g))2, E[Sg] = Rg − 1
Rg
(1− ρg). (4.13)
For gene g, we test the differential expression in 2 steps. First, we take genes with z¯(g) less
than 0.05 quantile for standard normal distribution as DE genes. This is a conservative
test because Var[z¯(g)] =
1+(Rg−1)ρg
Rg
< 1 when ρg ∈ [0, 1]. Then we focused on those genes
that do not passed the conservative test in the first step. We adjusted their variance by
estimating ρg via empirical Bayes. Since 0 ≤ ρg ≤ 1, it is natural that we use a beta prior
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with parameter a and b for ρg:
p(ρ|z(g)1 , . . . , z(g)Rg ) ∝ p(z
(g)
1 , . . . , z
(g)
Rg
|ρg) · p(ρg|a, b)
=
exp(−zgΣ−1g zg/2)√
(2pi)Rg |Σg|
ρa−1g (1− ρg)b−1, (4.14)
where
zg =

z
(g)
1
z
(g)
2
...
z
(g)
Rg

∼ N(0,Σg), Σg =

1 ρg · · · ρg
ρg 1 · · · ρg
...
...
. . .
...
ρg ρg · · · 1

Rg×Rg
.
The log-likelihood of ρg given zg is
log(p(ρg|z(g)1 , z(g)2 , . . . , z(g)Rg )) =constant−
1
2
[∑Rg
r=1(z
(g)
r )2
1− ρg −
ρgR
2
g z¯
2
g
(1− ρg)(1 + (Rg − 1)ρg)
]
− Rg − 1
2
log(1− ρg)− 1
2
log(1 + (Rg − 1)ρg)
+ (a− 1) log(ρg) + (b− 1) log(1− ρg) (4.15)
The summary statistics for log-likelihood (4.15) are Sg =
1
Rg
∑Rg
r=1(z
(g)
r )2 and z¯g =
1
Rg
∑Rg
r=1 z
(g)
r .
We estimate ρg with EM algorithm by iterating between Expectation and Maximization
step. The initial values for ρg is
ρ(0)g = 1−
RgSg
Rg − 1 . (4.16)
From iteration t to t+1, we update ρˆ
(t)
g to ρˆ
(t+1)
g as well as the beta distribution parameters
(a(t), b(t)).
E-step
ρˆ(t+1)g = E[ρ|zg, a(t), b(t)] =
∫ 1
0 p(ρ|zg, a(t), b(t)) · ρdρ∫ 1
0 p(ρ|zg, a(t), b(t))dρ
; (4.17)
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M-step
(a(t+1), b(t+1)) = ArgMaxa,b{(a− 1) log(ρˆ(t+1)g ) + (b− 1) log(1− ρˆ(t+1)g )}. (4.18)
With estimated ρˆg and the corresponding variance Sˆg =
1+(Rg−1)ρˆg
Rg
, we further select DE
genes that z¯g/
√
Sˆg less than 0.05 quantile of standard normal distribution.
4.3. Results
4.3.1. Constrained linear regression on counts data
In section 4.2, we described the expected behavior of the p-values and corresponding z-
values by comparing full model (4.1) and cell type model (4.4), when there is not differential
expression between healthy and diseased status. Traditional ANOVA test is designed for
comparing two linear models with homoscedasticity normal noises and is based on the
χ2 distribution of the sum-of-squared residuals. However, ANOVA test is not applicable
for model (4.1) and model (4.4) with normalized read counts as Xjg because of the non-
negativity constraints on the model parameters, βkg and αkg + βkg. Furthermore, the noise
term is not homoscedastic normal. Hence, the squared residuals can not be approximated
by a χ2 distribution.
Even though, we still checked the residuals from two models and calculated p-values from
residual sum of squares (RSS) under the null validation setting. The bulk RNA-seq data of
Fadista et al. (2014) includes Nd = 11 type 2 diabetes(T2D) subjects and Nh = 66 healthy
subjects. Their cell type proportions are estimated by MuSiC(Wang et al., 2019) with single
cell reference from Segerstolpe et al. (2016). Summary of single cell data and bulk data
are in Table 1. The deconvolution of Fadista et al. (2014) provides the estimated cell type
proportions of 6 major cell types: alpha, beta, delta, gamma, acinar and ductal with single
cell data from Segerstolpe et al. (2016).
To examine p-values distribution under the null hypothesis H01, we randomly assigned
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pseudo-labels to 66 healthy subjects, half labeled as healthy and half as diseased. Hence,
there are no DE genes between healthy and diseased groups. P-values from null distribution
validation are generated with the procedures in Section 4.2 and should follow uniform
distribution. First we deconvolve Fadista et al. (2014) with single cell reference Xin et al.
(2016) with a subset of the common genes (15659 genes) and repeated R = 100 times with
different subsets of genes. The estimated proportions for all 77 subjects are boxplotted in
Figure 10 with 80% of common genes selected (12527 genes) for deconvolution. Subjects
are ordered by increasing HbA1c levels from bottom to top, among which 66 subjects are
healthy and 11 subjects are diabetic. The estimated cell type proportions vary across
repetitions and this is due to different input genes for deconvolution.
One might ask why we use 80% of the common genes for deconvolution. Using different
number of genes for deconvolution will lead different variation of estimated proportions
across repetitions. In general, Using more genes for deconvolution leads to more consistent
estimated proportions across repetition. The estimated proportions directly influence the
results of “ reverse regression” of model (4.1) and (4.4) and we would lose power of detecting
differential expression genes using highly biased proportions estimated with a small subset
of genes. However, we can not afford of using too many genes for deconvolution while leave
only a few genes for DE tests because numerous repetitions are needed to guarantee that
all genes have multiple p-values. After tried different number of genes for deconvolution,
we choose 80% of the common genes.
To save computation time, we filtered out lowly expressed genes by average and maximum
counts per million (CPM) across subjects (X¯jg > 0.25 and maxXjg > 0.5). For the those
candidate genes, we repeated the randomly labeling L = 100 times and calculated the
p-values from a faked F-statistics constructed by residual squared sum (RSS),
FK+1,Nh−K−1 =
(RSSct − RSSfull)/(K + 1)
RSSct/(Nh −K − 1) ,
where RSSfull and RSSct are the RSSs from full model (4.1) and cell type model (4.4),
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Figure 10: Boxplot of estimated cell type proportions for 100 repetitions of Fadista et al.
(2014) dataset.
The bulk data is from Fadista et al. (2014) and the single cell reference for deconvolu-
tion is from Segerstolpe et al. (2016). Only 6 major cell types (color coded) are used for
deconvolution and input with randomly selected 80% of common genes.
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respectively and Nh is the number of healthy subjects. Even though FK+1,Nh−K−1 does not
follow F distribution, the p-values from F-distribution can still guide for finding DE genes
by constructing empirical distribution for p-values from the null distribution validation (see
Section 4.2). Here, we used the test statistics from KolmogorovSmirnov test (KS test)
(Stephens, 1974) to characterize the goodness-of-fit between observed average p-values and
uniform distribution on [0, 1]. The KS test statistics is the maximum absolute difference
between empirical distribution function and uniform distribution function, and small test
statistics means the data is more likely come from uniform distribution. The test statistics
calculated from the CPM of the healthy subjects from Fadista et al. (2014) are shown
in Figure 11a. Moreover, the average p-values from worst cases and those p-values are
concentrated near 1 (Figure 11b).
Figure 11: Null distribution validation with CPM and log-transformed CPM on Fadista
et al. (2014) dataset.
a. Histograms of KS test statistics. The histogram of test statistics when bulk expressions
are measured by CPM and log-transformed CPM are shown with green shadows and blue
shadows, respectively. The KS test are performed on all genes. b and c. QQ plot of average-
across-repetition p-values for all labels. b. Two genes with largest KS test statistics when
bulk expressions are measured by CPM. c. Two genes with largest KS test statistics when
bulk expression are measured by log-transformed CPM.
The faked F-statistics and the corresponding p-values are not reliable for testing cell type
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specific differential expression. There are proposed reasons why the faked F-statistics is not
reliable: (i) The noise term of model (4.1) and (4.4) do not follow normal distribution; (ii)
Residuals from constrained linear regression does not follow normal distribution even when
the noise term is from normal distribution; (iii) The degree of freedom for F-statistics is
not (K + 1, Nh −K − 1) when there exists an βkg or αkg on boundary of the constraints.
4.3.2. Log-transformed CPM
Currently, there is no good test statistics for comparing constrained linear regressions. Fur-
thermore, the noise is not normal homoscedastic. To eliminate the non-negative constraints
on expressions, we transformed CPM to log scale. Let Xjg = log(CPM + 1) and the pa-
rameters in full model (4.1), βkg and αkg, no longer represent cell type specific expression
and cell type specific differential expression, respectively, but represent cell type specific
parameters and the cell type specific differences between two conditions. Although we loose
part of the interpretability of our model, there are no constraints on parameters and it is
reasonable to assume homoscedastic normal for the noise term.
When Xjg = log(CPM + 1), the regression of model (4.1) estimates the parameters for cell
type proportions, the parameter for healthy/diseased conditions and the interaction between
proportions and conditions. The null hypothesis with log-transformed CPM models is the
same as H01 and tests the interaction between cell types and conditions. Now the null
hypothesis focuses on the difference of cell type parameters between healthy and diseased
conditions, rather than the cell type specific differential expression is zero or not. We test
H01 and generate the p-values by the ANOVA test.
With the same analysis steps as we did in the previous section and the same datasets
from Fadista et al. (2014), we checked the p-values under the null hypothesis, which are
calculated when bulk expressions are measured with log-transformed CPM (Figure 11a and
c). We first checked the goodness-of-it by comparing average-across-repetition p-values with
uniform distribution on [0, 1] by KS test, and the test statistics are plotted in Figure 11a.
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Comparing with the test statistics from modeling CPM, modeling log-transformed CPM
generates p-values that fit uniform distribution better. The worst case averaged-across-
repetition p-values align better along the x = y line in the QQ-plots (Figure 11c). This
confirms that the p-values from log-transformed CPM models are convincing and proper
for later analysis.
4.3.3. Benchmark validation
To examine the performance of MuSiC-DE, we construct a benchmark dataset with known
cell type specific DE genes. The benchmark dataset is an artificial bulk dataset that is
generated using single cell data from multiple subjects of both healthy and diseased status,
similar to the procedure described in Appendix A.2.2. In this section, we use the single cell
dataset from Xin et al. (2016) and there are 18 subjects (12 healthy and 6 T2D) with 4 cell
types: alpha, beta, gamma and delta. We constructed the cell type specific artificial bulk
data by summing up single cell read counts from cells of the same type for each subject.
Then, for each cell type, cell-type specific DE genes are identified by comparing the artificial
bulk data of that cell type between healthy and diseased conditions. We applied DESeq2
(Love et al., 2014) and selected genes with adjusted (by false discovery rate) p-values less
than 0.05. This yielded the 27, 96, 102, 13 DE genes respectively for alpha, beta, gamma
and delta cell types, which we will use as a benchmark for comparison.
Even though this is an intuitively logical way of developing a benchmark, we do not expect
complete overlap with the DE genes under our model, due to the fundamental difference
in modeling. DESeq2 selects genes by comparing the cell-type specific bulk data between
two conditions while MuSiC-DE selects genes from tissue-level bulk data by comparing two
models. When cell-type specific bulk is not observed, there are many limitations as to what
is estimable. In our results, we will explore these limitations.
Next, we tried to mimic the scenario where only tissue-level bulk sequencing is performed
for each subject, that is, the tissue-level artificial bulk data constructed by summing up
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single cell expression of the same subject from Xin et al. (2016) (see Appendix A.2.2).
Deconvolution, the estimation of the cell type proportions, uses single cell reference data
from Segerstolpe et al. (2016). In each partition, 80% of the common genes, in total 16101
genes are used for deconvolution. Comparing the estimated cell type proportions with
true proportions (Figure 12), the estimated proportions for alpha cells and beta cells more
accurate. For gamma cells and delta cells, which are relatively rare in the artificial bulk
data, it is more difficult to get accurate estimations.
Figure 12: Scatter plot of true cell type proportions versus estimated cell type proportions
from MuSiC over 100 repetitions.
The artificial bulk data is constructed from Xin et al. (2016) and the single cell reference
is from Segerstolpe et al. (2016). For each repetition, we randomly selected 80% of the
common genes between bulk data and single cell data. The estimate proportions for 4 cell
types (color coded) are shown on the y-axis while the true proportions are on x-axis. The
dot shows the median of estimated proportions and the errorbars indicate 0.3−0.7 quantile
of estimated proportions across 100 repetitions.
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Within each repetition, we randomly selected 80% of the common genes for deconvolution
and test DE for the remaining genes that have average CPM greater than 0.03. For the
rest of the analysis, we transformed the p-values from the ANOVA test to z-values and
investigated the z-values as derived in Section 4.2. First assume the z-values have mean
µg = 0 and variance σ
2
g = 1 for all genes under the null, we reject H01 for genes with low
z-values by the conservative test : z¯g < qnorm(0.05). For genes that do not passed the
conservative test, we adjusted their variance by estimating ρg from empirical Bayes using
all of the remaining genes after first conservative test. We assigned a beta prior to ρg ∈ [0, 1]
and the log-likelihood of ρg given zg is in equation (4.15). A total of 693 genes were selected
from conservative test, and in the second round, a total of 181 genes were selected by the
z-score computed using the adjusted variance. The null distribution validation of artificial
bulk data are discussed in Appendix A.3.1.
Figure 13: Smooth scatter plot of mean(z¯) versus variance(
√
S) across genes. The red line
is the cut-off for conservative test. The genes on the left of red line are the significant genes
from conservative test. The genes that are significant after adjustment of their variance are
denoted with green plus sign.
Table 3 shows the degree of overlap of MuSiC-DE with the benchmark DE genes favored
with cell-type specific artificial bulk. However, MuSiC-DE can only select a small part of
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the true cell type specific DE genes (Table 3), that is, MuSiC-DE tend to selects genes that
DESeq2 does not select. Seyednasrollah et al. (2013) argues that DESeq2 is a conservative
differential expression gene selection tool, which only selects part of the true DE genes. One
possible explanation for MuSiC-DE selecting more significant genes than DESeq2 is the
conservation of DESeq2. Another possible explanation for this phenomenon is that MuSiC-
DE tests the difference between two models by residuals rather than tests the difference
between expressions of healthy and diseased condition cell type by cell type. For example,
if the expression of a gene is different between healthy and diseased conditions for all cell
types, say the expression of healthy condition is higher than that of diseased condition.
Suppose the differences are too little to be detected by DESeq2 with adjusted p-values less
than 0.05. However, this gene has a high chance that will be selected by our method because
our method accumulates the differences between healthy and diseased conditions from all
cell types and tests the total difference by testing the difference of RSSs. To test differential
expression of a specific cell type, we need hypothesis H02 for all cell types. Even though our
cell type alpha beta delta gamma total(unique)
DESeq2 DE genes 27 96 102 13 235
MuSiC-DE & DESeq2 10 13 1 0 23
!MuSiC-DE& DESeq2 17 83 101 13 212
MuSiC-DE& !DESeq2 864 861 873 874 874
!MuSiC-DE & !DESeq2 19236 19170 19152 19240 19253
Table 3: Number of differential genes from cell type specific artificial bulk data.
method selects more genes than needed, we still can not detect true DE genes for delta and
gamma cells. One might suspect that the inaccurate estimated proportions of delta and
gamma cells lead to the lack of power in detecting true DE genes for those two cell types. We
can investigate this, as for this artificial dataset we know the true proportions. Therefore,
we use the true proportions in the full model 4.1 and cell type model 4.4 to compute a
z-value for each gene. This z-value can be compared to the average z-value we computed
across random partitions, where the true proportions are masked (Figure 12). From here,
we learn two things: One, the z-values from estimated proportions do correlate with the
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z-values from true proportions, but substantial error is introduced due to estimation of
proportions. Second and most importantly, even with the true proportions, MuSiC-DE still
missed most of the the DE genes detected DESeq2 for delta cells and gamma cells. The lack
of power of detecting DE genes for rare cell type is due to reasons other than inaccurate
estimated proportions.
Here we propose another explanation for the failure of detecting DE genes for rare cell
types. In linear regression, if there is no variation for a covariate in the design matrix, we
can not estimate the coefficient for that covariate because the covariate is collinear with
the intercept. In model (4.1), the covariates for αkg are (p1kt1, . . . , pNktN )
T . For a rare cell
type k, the covariates are close to 0 or equal to 0 and eliminating this covariates does not
change the RSS of linear regression even if the estimated αkg differs from 0. This limits the
power of detecting the true DE genes for rare cell types.
Now, let’s look at alpha and beta cells. Although MuSiC-DE detected some of DE genes
DESeq2 suggests, there still exists a group of DE genes MuSiC-DE missed. The genes that
DESeq2 selected for alpha and beta cell types are differential expressed and their p-values,
computed DESeq2, are less 0.05 after adjusting for FDR. In general, among those DE genes,
the gene are also chosen by our MuSiC-DE have lower p-values, provided by DESeq2, than
those that are not selected (Figure 15). However, we still missed some significantly differ-
ential expressed gene with extremely low p-values from DESeq2. Some of the missed DE
genes even have their average z-value greater than 0, which means the variance adjustment
of z-values does not help correct the test statistics in this case. Explored the coefficients
from the regression model (4.1) of the genes that are significant in DESeq2 but are missed
by MuSiC-DE, we proposed an explanation for this phenomenon. This may due to the
variation across subjects are largely explained by the rare cell type proportions. Adding
extra covariates for differential expression does not make more contribution for explaining
the variance of the bulk expression. In the space spanned by 4 cell type proportions, most
of the bulk expression can be projected on the the direction of rare cell types. Additional
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Figure 14: Smooth scatter plots of z-values from true proportions and average z-values from
estimated proportions. The artificial bulk data constructed from Xin et al. (2016). The
black line is the x = y line and the red lines are the cut-off for DE. The small plots pointed
out the DESeq2 selected genes for each cell type.
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Figure 15: Violin plot of p-values from DESeq2 for alpha and beta cells
directions spanned by cell type specific differential expression can not more about the vari-
ation of bulk expression. In the linear regression context, the RSS with cell type model
is very low and adding more covariates can not further reduce the RSS. Therefore, simply
comparing the full model and cell type model is not enough to detect all true DE genes.
4.3.4. Results of Fadista et al. (2014) dataset
In this section, we analyze the dataset from Fadista et al. (2014) with MuSiC-DE and
compared the significant genes selected from MuSiC-DE and the DE genes selected from
bulk expression. We selected genes that have adjusted p-values less than 0.05 from DESeq2
as bulk DE genes. In total there are 713 genes selected.
The null distribution validation analysis using the expression of healthy subjects from
Fadista et al. (2014) confirms that using log-transformed CPM as bulk expression fits the
model assumption better and works better for the DE analysis (Section 4.3.2). We con-
tinued using log-transformed CPM to analyze the whole dataset, with both healthy and
diseased subjects, from Fadista et al. (2014) and find DE genes between two conditions.
The cell type proportions were estimated with single cell dataset from Segerstolpe et al.
(2016) (Figure 10) and the p-values are calculated by comparing the full model (4.1) and
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the cell type model (4.4). We transformed p-values to z-values and used z-values to detect
DE genes. After conservative test and variance adjustment by empirical Bayes with beta
prior on the correlation between repetitions, we selected 4586 differential expressed genes
(Figure 16). Compared with bulk DE genes selected by DESeq2 (Table 4), we focused on
genes that only selected by MuSiC-DE or only bulk DE genes.
Figure 16: Smooth Scatter plot of z-values from the analysis of Fadista et al. (2014). The
red line is the cut-off of conservative test.
a. The DE genes selected by MuSiC-DE includes the genes selected by conservative test,
which are shown on the left of the red line, and the genes selected by empirical Bayes, which
are shown with the green dots. b. The bulk DE genes are shown with black dots.
Bulk DE Bulk not DE Total
MuSiC-DE selected 505 4081 4586
MuSiC-DE not selected 208 14094 14302
Total 713 18175 18888
Table 4: Number of genes that are selected as differentially expressed by MuSiC-DE of
cell-type level and by DESeq2 of tissue level.
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4.4. Discussion
Diseases progression involves the shift of cell type compositions as well as the change of cell
type specific transcriptomic phenotype. The differential expression of bulk tissues between
disease and healthy cohorts is a mixture of the two shifts. To investigate the cell type specific
phenotype shifts from bulk tissues between cohorts, we need to separate the phenotype
shifts from cell type proportions. Deconvolution methods provide a way to estimate cell
type proportions. Some deconvolution methods require using marker genes, that is, the
genes only expressed in a specific cell type. However, cell type specific expression changes
can also be observed in marker genes and the deconvolution methods with markers may
lead to biased proportions that treat the cell type specific expression changes as cell type
proportion changes.
In this chapter, we proposed a method to study the cell type specific differential expres-
sion using bulk sequencing data on samples between healthy and diseased condition using
estimated cell type proportions by reverse regression. Differential expression of each gene
is tested multiple times with cell type proportions estimated by MuSiC, a deconvolution
method without marker gene selection, excluding this gene from input. We compared two
linear models, the full model and the cell type model, to calculated p-values. Compared
to cell type model, the full model include the interaction term between diseased indicator
and cell type proportions. We modeled the p-values to select cell type specific DE genes
and called this method as MuSiC-DE. The p-values generated with null distribution using
dataset from Fadista et al. (2014) suggests that we should use log-transformed CPM to
measure bulk expression for detecting cell type specific DE genes. We also examined our
method on benchmark dataset from Xin et al. (2016) by comparing the cell type specific DE
genes selected from cell type specific artificial bulk data by DESeq2 and the genes selected
by MuSiC-DE. The fundamental difference between two methods yields that the DE genes
selected by our method will not full agree with the DE genes selected by DESeq2 and we
investigated and explained the discrepancies between DE genes selected by two methods.
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We also studied the performance of MuSiC-DE on datasets from Fadista et al. (2014).
The analysis of MuSiC-DE is not completed. In future study, we want to benchmark MuSiC-
DE in a better way, rather than comparing MuSiC-DE selected genes with genes selected
by DESeq2, which is not a golden standard of differential expression. We also would like
to extend our method such that we are able to match DE genes to certain cell types. More
datasets should be involved for the examination of MuSiC-DE. We will improve MuSiC-DE
in our future research.
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APPENDIX
A.1. Supplementary Information for Allele specific Mendelian randomization
A.1.1. Simulation results with extreme instrumental variable strength
Figure 17: Simulation results when changing instrument strength by changing the mean of
W , µw.
Figure 18: Simulation results when changing instrument strength by changing the variance
of W , σw.
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A.2. Supplementary Information for bulk tissue cell type proportion deconvolution
with single cell reference
A.2.1. Linear regression to examine the relationship between estimated cell type proportion
and HbA1c level
The linear regression results, mentioned in section 3.3, that examine the relationship be-
tween estimated cell type proportion and HbA1c level are shown Table 5 and 6. Table 5
contains the results with single cell data from Segerstolpe et al. (2016) as reference while
Table 6 uses Baron et al. (2016) as reference. Full deconvolution results with Baron et al.
(2016) are shown in Figure 19.
A.2.2. Construction of artificial bulk tissue RNA-seq data
We construct artificial bulk tissue RNA-seq data by summing up read counts across all cells
from the same subject in the single-cell RNA-seq data. By way of construction, the cell
type proportions of the artificial bulk data are equal to the observed cell type proportions
in the single-cell data, and this allows us to compare estimated cell type proportions from
various methods with the true proportions. Figure 20b shows that the artificial bulk tissue
RNA-seq data have similar gene expression as the real bulk RNA-seq data generated from
the same subjects.
A.2.3. Impact of vary cell type proportions of artificial bulk data in deconvolution
Figure 8b in the main text shows the deconvolution results from MuSiC, NNLS, BSEQ-sc
and CIBERSORT, and these results indicate that the alpha cell proportion is over-estimated
by all methods except for MuSiC. To evaluate the impact of different cell type proportions
in the bulk data on deconvolution estimates, we generated additional artificial bulk data to
show that MuSiC can still reliably estimate cell type proportions even when the true cell type
proportions in the bulk data are very different from the cell type proportions in the single-
cell reference. In this newly constructed benchmark data, the single-cell reference stays the
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Cell type MuSiC BSEQ-sc
Estimate Std.Error P value Estimates Std.Error P value
alpha (Intercept) 0.380382 0.207754 0.07125 1.351464 0.240052 3.26E-07
HbA1c -0.00203 0.027737 0.941834 -0.07377 0.032049 0.024249
Age -0.00097 0.001935 0.617836 0.002753 0.002236 0.222198
BMI -0.00167 0.007945 0.834127 -0.01711 0.00918 0.066449
Gender 0.033135 0.042881 0.442221 -0.00638 0.049548 0.897869
beta (Intercept) 0.877022 0.190276 1.71E-05 0.065847 0.046433 0.16047
HbA1c -0.0614 0.025403 0.01819 -0.00295 0.006199 0.635957
Age 0.002639 0.001772 0.140873 0.000576 0.000433 0.187339
BMI -0.01362 0.007276 0.065293 -0.00162 0.001776 0.365258
Gender -0.07987 0.039274 0.04566 -0.00541 0.009584 0.574159
gamma (Intercept) 0.008556 0.010504 0.417988 0.102201 0.024366 7.69E-05
HbA1c 0.001047 0.001402 0.457785 -0.00278 0.003253 0.396334
Age 9.21E-05 9.78E-05 0.349431 -0.00013 0.000227 0.570225
BMI -0.00057 0.000402 0.160731 -0.00207 0.000932 0.029738
Gender -0.00165 0.002168 0.450416 -0.00092 0.005029 0.855252
delta (Intercept) 0.057678 0.010592 6.81E-07 0.015539 0.018715 0.409122
HbA1c -0.00106 0.001414 0.455427 0.002017 0.002499 0.422131
Age -0.00016 9.87E-05 0.12039 9.99E-05 0.000174 0.568316
BMI -0.0011 0.000405 0.008142 -0.00103 0.000716 0.154263
Gender 0.000424 0.002186 0.846817 -0.00254 0.003863 0.512616
acinar (Intercept) -0.10619 0.131102 0.420638 -0.14553 0.052092 0.006672
HbA1c 0.034967 0.017503 0.049519 0.019075 0.006955 0.007684
Age -0.00247 0.001221 0.046841 0.00066 0.000485 0.178153
BMI 0.00662 0.005013 0.190883 0.002008 0.001992 0.316847
Gender 0.05332 0.02706 0.052632 -0.02338 0.010752 0.032985
ductal (Intercept) -0.21745 0.141008 0.127428 -0.38952 0.232841 0.098686
HbA1c 0.028474 0.018826 0.134781 0.058397 0.031086 0.064353
Age 0.000863 0.001313 0.513005 -0.00396 0.002169 0.072066
BMI 0.010341 0.005392 0.059097 0.019814 0.008904 0.029191
Gender -0.00536 0.029105 0.854406 0.038631 0.048059 0.424144
Table 5: Linear regression to examine the relationship between estimated cell type propor-
tions (Segerstolpe et al. (2016) as reference) and HbA1c levels. The fitted linear model is
estimated cell type proportion ∼ HbA1c + Age + BMI + Gender. Significant results (p
value < 0.05) are highlighted.
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Cell type MuSiC BSEQ-sc
Estimate Std.Error P value Estimates Std.Error P value
alpha (Intercept) 1.000504 0.275906 0.000533 1.220529 0.187349 8.56E-09
HbA1c -0.0259 0.036835 0.48424 -0.06398 0.025012 0.012632
Age 0.000234 0.00257 0.927855 0.001921 0.001745 0.274661
BMI -0.01137 0.010551 0.28475 -0.00681 0.007164 0.345275
Gender 0.038364 0.056948 0.502676 -0.02104 0.038669 0.588048
beta (Intercept) 0.315176 0.09427 0.001316 0.011001 0.016796 0.51455
HbA1c -0.02843 0.012586 0.026936 -3.70E-05 0.002242 0.986889
Age -0.00081 0.000878 0.361952 0.000142 0.000156 0.366396
BMI -0.00158 0.003605 0.661813 -0.00044 0.000642 0.498345
Gender -0.00927 0.019458 0.635249 -0.00079 0.003467 0.819685
gamma (Intercept) -0.0172 0.055935 0.759333 0.040372 0.011566 0.000827
HbA1c 0.001227 0.007468 0.869925 7.31E-05 0.001544 0.962362
Age 0.00085 0.000521 0.107295 -8.47E-05 0.000108 0.434521
BMI -0.00042 0.002139 0.843112 -0.0011 0.000442 0.015394
Gender -0.00998 0.011545 0.390355 -0.00048 0.002387 0.842519
delta (Intercept) 0.043785 0.009622 2.12E-05 0.012347 0.016882 0.466922
HbA1c -0.00121 0.001285 0.349663 0.002763 0.002254 0.224153
Age -8.79E-05 8.96E-05 0.330262 5.00E-05 0.000157 0.751577
BMI -0.00093 0.000368 0.013618 -0.00101 0.000646 0.1226
Gender -0.00063 0.001986 0.753674 -0.00098 0.003484 0.780352
acinar (Intercept) 0.002232 0.042169 0.957925 -0.23299 0.083467 0.006714
HbA1c 0.013032 0.00563 0.023475 0.034902 0.011143 0.00251
Age -0.00062 0.000393 0.119068 -0.00015 0.000777 0.848086
BMI -0.0008 0.001613 0.621478 0.006564 0.003192 0.043362
Gender 0.013342 0.008704 0.129687 -0.01866 0.017228 0.282488
ductal (Intercept) -0.3445 0.218745 0.119669 -0.05126 0.14 0.715354
HbA1c 0.041276 0.029204 0.161852 0.026281 0.018691 0.164004
Age 0.00043 0.002038 0.833485 -0.00188 0.001304 0.153951
BMI 0.015109 0.008365 0.075051 0.002786 0.005354 0.604398
Gender -0.03183 0.04515 0.483036 0.04194 0.028896 0.151016
Table 6: Linear regression to examine the relationship between estimated cell type pro-
portions (Baron et al. (2016) as reference) and HbA1c levels. The fitted linear model is
estimated cell type proportion ∼ HbA1c + Age + BMI + Gender. Significant results (p
value < 0.05) are highlighted.
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Figure 19: Estimated cell type proportions of the pancreatic islet bulk RNA-seq data in
Fadista et al. (2014) with single cell reference from Baron et al. (2016). The analysis is
similar to Figure 8c-d in the main text except that the single-cell reference are based on the
three healthy subjects from Baron et al. (2016) and the MuSiC estimation was adjusted for
protocol bias as described in section 3.2. a. Jitter plot of the estimated cell type proportions
for Fadista et al. (2014) subjects, color-coded by deconvolution methods. 77 out of the 89
subjects from Fadista et al. (2014) that have recorded HbA1c levels are plotted. T2D
subjects are denoted as triangles. b. HbA1c levels vs beta cell type proportions estimated
by each of the four methods. The reported p-values are from single variable regression
beta cell proportions HbA1c. Multivairiable regression results adjusting for age, BMI and
gender are reported in Table 6.
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Figure 20: Exploratory analysis of single-cell RNA-seq data from Segerstolpe et al. (2016).
a. Example of cross-subject and cross-cell variation in cell type specific gene expression.
The boxplot contains 4 cell types: alpha, beta, gamma, and delta cells from Segerstolpe
et al. (2016) single-cell RNA-seq data. The x-axis is the log transformed average relative
abundance across cells from the same cell type, and the y-axis is the subject label. The rel-
ative abundance of gene GC is widely spread across the x-axis while the relative abundance
of gene TTR is more concentrated across subjects. We consider gene GC as non-informative
and TTR as informative. b. Comparison of log transformed relative abundance levels be-
tween real bulk tissue RNA-seq data and artificially constructed bulk RNA-seq data for the
same subject. Single-cell and bulk tissue RNA-seq data are both from Segerstolpe et al.
(2016). Each dot represents a gene and the gray line is x = y. c. Heatmap of true and
estimated cell type proportions. In addition to the four methods described in the main text,
we also evaluated the estimates given by MuSiC and NNLS when using only the marker
genes used in BSEQ-sc.
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same while we construct the artificial bulk data from Xin et al. (2016) by combining cells
from 2 subjects with 75% alpha cells dropped. In this way, beta cells become the dominant
cell type in the artificial bulk data, as expected for real bulk tissue. Figure 21c shows that
only MuSiC recovers the true cell type composition, revealing that beta cells are the major
cell type in the artificial bulk data, whereas the other methods overestimate the alpha cell
proportion, indicating that these methods are more likely to be influenced by the cell type
proportions in the single-cell reference. This analysis also gives the likely explanation for
why, in the Fadista et al. (2014) data, all methods that rely on CIBERSORT marker genes
grossly overestimate alpha cell proportion.
A.2.4. Impact of missing cell types in single-cell reference on deconvolution
One of the limitations of single-cell RNA-seq is cell loss during cell dissociation. This
not only biases cell type proportions, but also leads to failure of detecting certain cell
types, especially those rare cell types. In practice, the single-cell reference dataset might
be incomplete, and not every cell type present in the bulk data is included in the single-
cell reference. Since the deconvolution methods rely on observed cell types in the single-cell
reference, it is important to evaluate whether cell type proportions can be reliably estimated
when some cell types are missing in the single-cell reference.
We evaluate MuSiC, NNLS, BSEQ-sc and CIBERSORT with missing cell types (Figure
22, Table 7). The artificial bulk data consist of 6 cell types while the single-cell reference
only consists of 5 cell types. The evaluation shows that when major cell types are missed,
none of the methods can give accurate estimates. However, the cell type proportions are
estimated accurately by MuSiC when the missing cell type is not the dominant cell type in
the bulk tissue.
A.2.5. Tolerance of bias in single-cell relative abundance on deconvolution
The protocol discrepancies between bulk and single-cell datasets may lead to estimation
bias. To evaluate the degree of bias tolerance relative to the biological signal, we manually
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Figure 21: Heatmaps of true and estimated cell type proportions of artificial bulk data
constructed using single-cell RNA-seq data from Xin et al. (2016). a. Deconvolution results
when the single-cell reference is from the 6 healthy subjects of Segerstolpe et al. (2016)
with leave-one-out, i.e., for each subject under deconvolution, only single-cell data from
the remaining 5 subjects were used as single-cell reference. b. Deconvolution results when
the single-cell reference is from the 12 healthy subjects of Xin et al. (2016) with leave-one-
out, i.e., for each subject under deconvolution, only single-cell data from the remaining
11 subjects were used as single-cell reference. c.The cell type proportions for the artificial
bulk data are manually adjusted so that beta cells are the dominant cell type, as expected
in real bulk tissue. Alpha cells dominate in the scRNA-seq data due to dissociation and
capture bias. Thus, this analysis mirrors the real data analysis scenario where cell type
proportions differ substantially between scRNA-seq reference and bulk tissue. In more
detail, we combined cells from two subjects as one artificial bulk tissue RNA-seq dataset,
for example, H1.2 combined cells from subject H1 and H2. Then we dropped 75% of the
alpha cells at random. The single-cell reference is from the 6 healthy subjects of Segerstolpe
et al. (2016). Here, all methods that rely on pre-selected marker genes from CIBERSORT
are heavily biased by the cell type proportions in the single cell reference, and miss the true
cell type proportions in the bulk tissue data. In comparison, MuSiC is able to adjust to the
difference between scRNA-seq reference and bulk data.
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Figure 22: Heatmaps of true and estimated cell type proportions with missing cell types in
single-cell reference.
The artificial bulk data and the single-cell reference are both from Segerstolpe et al. (2016).
We constrained our analysis to the 6 major cell types: alpha, beta, delta, gamma, acinar
and ductal cells. The artificial bulk data is constructed by summing read counts from the 6
major cell types while the single-cell reference contains only 5 cell types (the column header
shows the cell type that is missing in the single-cell reference). The x-axis labels cell types
used in the single-cell reference and the y-axis shows the subject label. The top panel shows
the true composition, while panels below it show the results from each method. See Table
7 for detailed evaluation results.
82
alpha(0.447) RMSD mAD R beta(0.137) RMSD mAD R
MuSiC 0.13 0.09 0.72 MuSiC 0.04 0.03 0.98
NNLS 0.27 0.18 0.42 NNLS 0.12 0.08 0.86
BSEQ-sc 0.17 0.12 0.58 BSEQ-sc 0.12 0.08 0.87
CIBERSORT 0.12 0.09 0.77 CIBERSORT 0.09 0.06 0.91
delta(0.092) RMSD mAD R gamma(0.062) RMSD mAD R
MuSiC 0.04 0.03 0.98 MuSiC 0.05 0.038 0.97
NNLS 0.12 0.08 0.82 NNLS 0.12 0.081 0.84
BSEQ-sc 0.12 0.08 0.85 BSEQ-sc 0.12 0.083 0.86
CIBERSORT 0.10 0.07 0.90 CIBERSORT 0.10 0.070 0.90
acinar(0.092) RMSD mAD R ductal(0.062) RMSD mAD R
MuSiC 0.05 0.04 0.97 MuSiC 0.050 0.037 0.97
NNLS 0.11 0.07 0.85 NNLS 0.067 0.046 0.96
BSEQ-sc 0.14 0.10 0.79 BSEQ-sc 0.084 0.064 0.93
CIBERSORT 0.07 0.05 0.93 CIBERSORT 0.076 0.058 0.94
Table 7: Evaluation of deconvolution methods when there are missing cell types in the
single-cell reference. The missing cell type is shown in bold and the proportions in the bulk
tissue data are shown in parentheses.
introduce noise to cross-subject average of the single-cell obtained relative abundance θkg .
Because of the constraint that
∑G
g=1 θ
k
g = 1, we generate biased relative abundance by
Dirichlet distribution, denoted by θkg
′
. Consider one cell type only. For simplicity, we drop
the superscript k for cell type. We assume the relative abundances of G genes follow a
Dirichlet distribution,
(θ′1, . . . , θ
′
G) ∼ Dirichlet(t× (θ1, . . . , θG)), (A.1)
where t is a scaling factor. The mean and variance of θ′g are θg and
θg(1−θg)
t+1 , respectively.
By setting t = 999, 1332, 1999 and 3999, corresponding to
Var[θ′g]
E2[θ′g]
≈ (θg(1+ t))−1 ≥ 2, 1.5, 1
and 0.5, we simulated 100 times the cross-subject average of relative abundance of 6 major
cell types from Segerstolpe et al. (2016). We deconvolved the artificial bulk data constructed
by Xin et al. (2016) (Figure 23) and MuSiC provides accurate cell type proportions even
with biased relative abundance as input.
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A.2.6. Robustness to single-cell dropout noise on deconvolution
Single-cell RNA-seq data are prone to gene dropout and the dropout rates can differ across
datasets. To evaluate the robustness of MuSiC, NNLS, BSEQ-sc and CIBERSORT to
dropout in single-cell data, we constructed artificial bulk data from the original scRNA-seq
data and deconvolve it by single-cell data with additional dropout noise. Following Jia et al.
(2017), the dropout rate pijgc is generated by
pijgc =
1
1 + k exp (k lnXjgc)
, (A.2)
where Xjgc is the observed read counts, k is the dropout rate parameters. The simulated
read count Xjgc
′ follows distribution such that
P (Xjgc
′ = Xjgc) = pijgc, P (Xjgc′ = 0) = 1− pijgc. (A.3)
We evaluated four different dropout rates with k = 1, 0.5, 0.2 and 0.1 (Figure 23). In
general, adding more dropout noise leads to lower MuSiC estimation accuracy. Compared
with other methods, MuSiC consistently performs better in the presence of dropout noise.
A.2.7. Convergence of MuSiC with different starting points
MuSiC estimates cell type proportions by weighted non-negative least square (W-NNLS),
which might be sensitive to choice of starting values. To examine the convergence property
of MuSiC, we re-analyzed the data in Figure 8 to show convergence with different starting
points. The artificial bulk data is constructed by Xin et al. (2016) while the single-cell refer-
ence consists of 6 healthy subjects from Segerstolpe et al. (2016). The cell type proportions
of four cell types: alpha, beta, delta and gamma are estimated using MuSiC with different
starting points are shown in Table 8. W-NNLS converges to the same value regardless of
the starting points (Figure 24).
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Figure 23: Benchmark evaluation of robustness of MuSiC.
a. and b. evaluate the impact of different dropout rate in scRNA-seq (Section A.2.6). a.
and b. show heatmaps of MuSiC estimated cell type proportions. The single-cell reference
is based on six healthy subjects from Segerstolpe et al. (2016) with different dropout rates.
The artificial bulk data of a. is constructed by Segerstolpe et al. (2016) while b. is
constructed by Xin et al. (2016) c. Evaluation of the impact of biased relative abundance
84 in the single-cell reference (Section A.2.5). Boxplot shows three evaluation metrics from
100 simulations of MuSiC estimated cell type proportions with biased relative abundance,
color-coded by scale parameter of Dirichlet distribution. The horizontal lines show the
evaluation metrics of four methods without bias in the single-cell reference. d. Heatmap
of MuSiC estimated cell type proportions with RPKM as the input. The artificial bulk
data and single-cell reference are both from Segerstolpe et al. The estimation follows leave-
out-one rule. We utilized the average library size ratio of the six healthy subjects from
Segerstolpe et al. (2016) as the ratio of cell size.
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Cell type EQ SP1 SP2 SP3 SP4 SP5 SP6 SP7 SP8
alpha 0.25 0.4 0.2 0.2 0.2 0.7 0.1 0.1 0.1
beta 0.25 0.2 0.4 0.2 0.2 0.1 0.7 0.1 0.1
delta 0.25 0.2 0.2 0.4 0.2 0.1 0.1 0.7 0.1
gamma 0.25 0.2 0.2 0.2 0.4 0.1 0.1 0.1 0.7
Table 8: Starting points for convergence analysis
Figure 24: Convergence of MuSiC with different starting points.
The evaluation is performed on artificial bulk data, constructed by single-cell data from Xin
et al. (2016) while the single -cell reference is from Segerstolpe et al. (2016). We evaluate
the convergence of MuSiC with nine different starting points of four cell types in Table 8.
The iteration numbers are normalized between 0 and 1 for comparison. We plotted the
normalized iteration against estimated proportions for each subjects in Xin et al. (2016)
colored by cell types. From different starting points, estimated cell types converged to the
same proportions.
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A.2.8. Additional information of mouse kidney data
The benchmark evaluation procedure is the same as described in section3.3.
Figure 25: Benchmark evaluation using mouse kidney single-cell RNA-seq data from Park
et al. (2018). The artificial bulk RNA-seq data is constructed by summing read counts
across cells in all 16 cell types while the single-cell reference only consists of 13 cell types.
The other 3 cell types were discarded in the single-cell reference because they are too rare.
a. Heatmap of estimated cell type proportions and evaluation results. b. Scatter plot of
real cell type proportions versus estimated cell type proportions.
Estimated cell type proportions and correlation of the estimated cell type proportions across
samples for bulk RNA-seq data o rat renal tubule segments from Lee et al. (2015). Results
of MuSiC are shown in Figure 9e.
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Figure 26: Estimated cell type proportions and correlation of the estimated cell type pro-
portions across samples for bulk RNA-seq data of rat renal tubule segments (Lee et al.,
2015). Park et al. (2018) mouse single-cell RNA-seq data are used as reference. a. NNLS.
b. BSEQ-sc. c. CIBERSORT.
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The full results with 13 cell types from bulk data deconvolution. Summary of cell types of
Figure 27: Estimated cell type proportions of the 13 cell types in three real mouse bulk
RNA-seq datasets. a. Boxplot of estimated cell type proportions of 10 mice (4 APOL1
disease mice and 6 control mice) from Beckerman et al. (2017). b. Line plot of cell type
proportion changes after FA induction (Craciun et al., 2016) at 6 time points. There are 3
replicates at each time point and the average proportions are plotted. N: normal. c. Line
plot of cell type proportions of control (Sham operated mice), 2 days and 8 days after UUO
(Arvaniti et al., 2016).
Park et al. (2018) single cell dataset.
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Cell Type Abbr. # Cell % Cell Cell Type Abbr. # Cell % Cell
Endothelial Endo 1,001 2.29 Fibroblast Fib 549 1.26
Podocyte Podo 78 0.18 Macrophage Macro 228 0.52
Proximal tubule PT 26,482 60.54 Neutrophil Neutro 74 0.17
Loop of Henle LOH 1,581 3.61 B lymphocyte B lymph 235 0.54
Distal convo-
luted tubule
DCT 8,544 19.53 T lymphocyte T lymph 1,308 2.99
Collecting duct
principal cell
CD-PC 870 1.99
Natural killer
cell
NK 313 0.72
Collecting duct
intercalated cell
CD-IC 1729 3.95
Novel cell type
1
Novel 1 601 1.37
Collecting duct
transitional cell
CD-Trans 110 0.25
Novel cell type
2
Novel 2 42 0.10
Table 9: Summary of cell types of Park et al. (2018) single-cell dataset. Park et al. (2018)
sequenced 57,979 cells from healthy mouse kidneys and identified 16 cell types. As suggested
in Park et al. (2018), we limited our consideration to the 13 confidently characterized cell
types and eliminated CD-Trans and 2 novel cell types in our deconvolution analyses.
Abbrv. Full Segment Name Abbrv. Full Segment Name
S1 S1 proximal tubule mTAL medullary thick ascending limb
S2 S2 proximal tubule cTAL cortical thick ascending limb
S3 S3 proximal tubule DCT distal convoluted tubule
SDL short descending limb LDLIM long descending limb, inner medulla
LDLOM long descending limb CCD cortical collecting duct
CNT connecting tubule OMCD outer medullary collecting duct
tAL thin ascending limb IMCD inner medullary collecting duct
Table 10: Renal tubule segment names. Abbreviations and full names.
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Rank Segerstolpe Xin Fadista Rank Segerstolpe Xin Fadista
1 GCG GCG MALAT1 51 ITM2B EIF4A2 RPS3A
2 TTR MALAT1 EEF1A1 52 ENPP2 CTSD RPL9
3 MALAT1 INS TTR 53 ATP1A1 RBP4 SOD2
4 SERPINA1 TTR FTH1 54 ANXA4 HNRNPH1 EIF4B
5 SPP1 FTL GCG 55 HNRNPH1 BSG HSPA8
6 B2M PPP1CB CPE 56 ALDOB EEF2 PKM
7 FTH1 PCSK1N GNAS 57 CD164 RPS3 SCG2
8 CHGA CHGB RPL4 58 HLA-A PDK4 RPS24
9 PIGR PSAP APP 59 RIN2 SSR1 CD74
10 IAPP CHGA CTSD 60 ASAH1 SCD SQSTM1
11 SST EGR1 HSP90AA1 61 TMSB10 DNAJC3 TMBIM6
12 FTL SRSF6 RPLP0 62 BSG SAR1A TXNRD1
13 CALM2 FTH1 RPL7A 63 CLDN4 GPX4 LCN2
14 CHGB HSP90AB1 HSP90AB1 64 TMEM59 PLD3 RPL14
15 SERPINA3 SPINT2 HSP90B1 65 PPY ATP6AP1 PDIA3
16 ACTG1 MAP1B UBC 66 C10orf10 ANP32E HDLBP
17 SCG5 RIN2 CANX 67 HSPA8 TBL1XR1 HNRNPK
18 ALDH1A1 GNAS PAM 68 REG1B GNB2L1 SCARB2
19 TM4SF4 SCG5 RPS6 69 P4HB SLC22A17 RPL13A
20 REG3A CSNK1A1 SERPINA3 70 LCN2 PAFAH1B2 LINC00657
21 GAPDH PTEN EIF4G2 71 PKM RTN4 DSP
22 PPP1CB TSPYL1 RPS4X 72 ATP6V0B TMED4 SPINT2
23 ACTB C6orf62 HSPA5 73 PSAP CST3 REG1B
24 PRSS1 RPL3 ITGB1 74 LRRC75A-AS1 CD63 HNRNPC
25 RBP4 DPYSL2 IAPP 75 S100A11 TOB1 RPL15
26 GDF15 UBC TPT1 76 MUC13 HLA-A ENO1
27 COX8A SCG2 RPL5 77 MAP1B CLU RPS11
28 ALDOA ALDH1A1 SLC7A2 78 CD59 TTC3 GANAB
29 PDK4 PFKFB2 HNRNPA1 79 SLC30A8 RPS11 CDH1
30 RPL8 CPE ANXA2 80 CPE G6PC2 PEG10
31 H3F3B C10orf10 RPL7 81 CLPS GRN CLDN4
32 IGFBP7 TMBIM6 RPS18 82 CTSD SERPINA1 GSTP1
33 S100A6 CRYBA2 PCSK1 83 ATP1B1 SSR4 TUBA1A
34 EEF2 FTX ATP1A1 84 OLFM4 RPS6 RPS27A
35 TIMP1 HSPA8 IDS 85 TAGLN2 OAZ1 PRPF8
36 CFL1 HSP90AA1 GDF15 86 SCGN MARCKS HSPB1
37 GRN H3F3B RPS3 87 SERPING1 RPL15 RPS8
38 SPINT2 SLC30A8 RPSA 88 WFS1 SQSTM1 RPS12
39 SQSTM1 TLK1 CSDE1 89 LAPTM4A RASD1 ACLY
40 KRT19 ETNK1 CLTC 90 TAAR5 DSP MSN
41 CD63 B2M RPL10 91 SLC22A17 COX8A HNRNPA2B1
42 SLC40A1 DDX5 YWHAZ 92 RPL3 TIMP1 CTNNB1
43 G6PC2 FOS RPL3 93 HERPUD1 ATP1B1 MORF4L1
44 REG1A MAFB SLC30A8 94 CD24 WFS1 SERINC1
45 DDX5 CD59 RPL6 95 CALR PRDX3 KRT19
46 PCBP1 TM4SF4 TMSB10 96 CLDN7 CHP1 NCL
47 C6orf62 TMEM33 CD44 97 LAMP2 YWHAE GPX4
48 CRYBA2 CAPZA1 NPM1 98 CST3 FAM46A GNB1
49 CD74 CALM2 B2M 99 TMBIM6 RUFY3 RPS7
50 HLA-E GPX3 PABPC1 100 CTSB C4orf48 SEP2
alpha beta delta gamma acinar ductal
Table 11: Top 100 Genes with highest weights in the pancreatic islet analysis. The
bulk/artificial bulk data are from Segerstolpe et al. (2016), Xin et al. (2016) and Fadista
et al. (2014) and the single cell reference is obtained from 6 healthy subjects from Segerstolpe
et al. (2016). This table is color-coded by well-known marker genes.
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Rank Beckerman Craciun Arvaniti Rank Beckerman Craciun Arvaniti
1 Kap Malat1 Malat1 51 Cycs Dbi Rps14
2 mt-Atp6 Kap Kap 52 Rplp1 Rps18 Cox4i1
3 Gpx3 mt-Atp6 Gpx3 53 Rpl23 Rps14 Rpl26
4 mt-Co1 Gpx3 S100g 54 Gatm Cycs Cox5a
5 mt-Cytb mt-Co1 Ftl1 55 Rpl32 Cox4i1 Rps19
6 S100g mt-Cytb Fth1 56 Cyb5a Uqcrb Rpl10
7 mt-Co3 S100g Rps29 57 Acsm2 Ndrg1 Ttc36
8 mt-Co2 mt-Co3 Xist 58 Guca2b Rpl10 Rpl35
9 mt-Nd4 mt-Co2 Rpl37a 59 Uqcrb Rpl26 Gm8730
10 mt-Nd1 mt-Nd4 Rpl41 60 Rps14 Rps19 Dnase1
11 Ftl1 mt-Nd1 Fxyd2 61 Cox4i1 Acsm2 Itm2b
12 Fth1 Ftl1 Rpl38 62 Rpl26 Rpl35 Rpl35a
13 Rps29 Fth1 Rpl37 63 Cox5a Cyb5a Rps24
14 mt-Nd2 Rps29 Miox 64 Rps19 Miox Gm10260
15 mt-Nd3 mt-Nd2 Eef1a1 65 Ttc36 Itm2b Atp5l
16 Rpl37a mt-Nd4l Rpl39 66 Rpl10 Rpl35a Slc34a1
17 Rpl41 mt-Nd3 Cox6c 67 Dnase1 Atp5l Aldob
18 Fxyd2 Rpl37a Rps28 68 Rpl35 Gm8730 Cela1
19 Rpl38 Rpl41 Rps27 69 Rpl35a Akr1c21 Ass1
20 Rpl37 Xist Cndp2 70 Atp5l Rpl28 Prdx1
21 Miox Fxyd2 Cyp4b1 71 Rps24 Slc34a1 Rpl28
22 Eef1a1 Rpl37 Ndufa4 72 Slc34a1 Prdx1 Rpl23a
23 Rpl39 Rpl38 Akr1c21 73 Gm8730 Aldob Rpl6
24 Cox6c Eef1a1 Atp1a1 74 Itm2b Rps27a Pck1
25 Rps28 Spink1 Acy3 75 Aldob Cox6a1 Gm10709
26 mt-Nd5 Rpl39 Atp5k 76 Cela1 Rps24 2010107E04Rik
27 Rps27 Rps28 Cox7c 77 Ass1 Rpl23a Cox6a1
28 Cndp2 Cox6c Klk1 78 Prdx1 Rps4x Slc25a5
29 Cyp4b1 Rps27 Ubb 79 Rpl28 Gm10709 Rps4x
30 Ndufa4 mt-Nd5 Atp5e 80 Rpl6 Slc25a5 Rps27a
31 Akr1c21 mt-Atp8 Rps2 81 Rpl23a Ppia Ldhb
32 Atp1a1 Atp1a1 Ndrg1 82 Pck1 Cox5a Cox6b1
33 Acy3 Cox7c Rps23 83 2010107E04Rik Rpl13 Rpl18a
34 Atp5k Ubb Gm10076 84 Cox6a1 Cox6b1 Calb1
35 Cox7c Atp5e Prdx5 85 Gm10709 Cox7a2 Rpl13
36 Klk1 Atp5k Rps1 8 86 Slc25a5 Gatm Atp5b
37 Atp5e Ndufa4 Tpt1 87 Rps27a Ass1 Rpl13a
38 Ubb Rps2 Chchd10 88 Rps4x Ndufa3 Cox7a2
39 Rps2 Rps23 Rplp0 89 Ldhb Rpl18a Ndufa3
40 Ndrg1 Gm10076 Dbi 90 Cox6b1 Cyp4b1 Slc27a2
41 Rps23 Klk1 Rpl29 91 Calb1 Atp5j Actb
42 Gm10076 Rps21 Rps21 92 Atp5b Cox8a Ppia
43 Prdx5 Rpl29 Rplp1 93 Cox7a2 Acy3 Rpl36a
44 Chchd10 Prdx5 Cycs 94 Rpl18a Rpl36a Atp5j
45 Tpt1 Rplp1 Rpl23 95 Ndufa3 Actb Chpt1
46 Rps18 Tpt1 Rpl32 96 Slc27a2 Ndufa13 Rps15a
47 Dbi Rpl23 Gatm 97 Rpl13 Rpl13a Hrsp12
48 Rps21 Rpl32 Acsm2 98 Rpl36a Ttc36 Ndufa13
49 Rplp0 Chchd10 Guca2b 99 Ppia 2010107E04Rik Cox8a
50 Rpl29 Rplp0 Uqcrb 100 Atp5j Gm10260 Ugt2b38
PT DCT CD-IC Podo T lymph
Table 12: Top 100 genes with highest weights in the mouse kidney analysis in Step 1 of
the tree-guided deconvolution procedure. The bulk/artificial bulk data are from Beckerman
et al. (2017), Craciun et al. (2016) and Arvaniti et al. (2016) and the single cell reference
is obtained by 7 healthy mice from Park et al. (2018). This table is color-coded by marker
genes.
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Immune Rank Beckerman Craciun Arvaniti Rank Beckerman Craciun Arvaniti
1 Cd74 Apoe Cd74 26 C1qb Npc2 C1qb
2 Lyz2 S100a6 Lyz2 27 Nkg7 Gzma Nkg7
3 Ccl5 S100a4 Ccl5 28 Ccl4 Capza2 Vim
4 H2-Aa Psap H2-Aa 29 Vim Ly6e Ccl4
5 H2-Ab1 Nkg7 H2-Ab1 30 Ly6c2 Ly6c2 Ly6c2
6 Tmsb10 Crip1 Tmsb10 31 Ms4a4b Serinc3 Ms4a4b
7 Gzma Cd3g Gzma 32 Sat1 Fos Sat1
8 H2-Eb1 Ccl3 H2-Eb1 33 C1qc Pou2f2 C1qc
9 Plac8 Ccnd2 Plac8 34 S100a10 Ctsz S100a10
10 Cst3 Slpi Cst3 35 H3f3a Cd74 H3f3a
11 Ifi27l2a Gm2a Ifi27l2a 36 Ctss Il7r Ctss
12 Slpi Ssr4 Slpi 37 Gngt2 H2afy Gngt2
13 Ifitm3 Lck Ifitm3 38 S100a6 Ctsb S100a6
14 Apoe Spi1 Apoe 39 S100a4 Ifngr1 S100a4
15 Tyrobp Fxyd5 Tyrobp 40 Lst1 Tgfb1 Lst1
16 Actg1 Ccl4 Actg1 41 Klf2 Sub1 Klf2
17 Crip1 Gzmb Crip1 42 Msrb1 Socs2 Msrb1
18 Fcer1g Cnn2 Fcer1g 43 H2afz Ifitm3 H2afz
19 Cebpb Id2 Cebpb 44 Wfdc17 Itgb7 Wfdc17
20 C1qa Cybb C1qa 45 Arpc1b Cd79a Arpc1b
21 AW112010 Sep1 AW112010 46 Ifitm2 Ltb Ltb
22 Ly6e Hsp90b1 Ly6e 47 Ltb Fyb Ifitm2
23 Id2 Itgb2 Id2 48 S100a11 Tspan32 S100a11
24 Psap Ccl6 Psap 49 Lgals3 Sat1 Mzb1
25 Lgals1 Lsp1 Lgals1 50 Mzb1 Xbp1 Lgals3
Epithelial Rank Beckerman Craciun Arvaniti Rank Beckerman Craciun Arvaniti
1 Hbb-bs Hbb-bs Hbb-bs 26 Gm5424 Slc12a3 Slc22a28
2 Hba-a1 Hba-a1 Hba-a1 27 Slc12a3 Slc22a28 Slc22a29
3 Umod Slco1a1 Slco1a1 28 Nrp1 Slc22a29 Emcn
4 Slco1a1 Slc22a6 Slc22a6 29 Igfbp5 Ly6c1 Car12
5 Slc22a6 Pvalb Nat8 30 Ehd3 Car12 Aspdh
6 Pvalb Nat8 Pvalb 31 Slc22a28 Aspdh Akr1c14
7 Nat8 Umod Mep1a 32 Slc12a1 Igfbp5 Ly6c1
8 Mep1a Mep1a Umod 33 Slc22a29 Akr1c14 Hexb
9 Egf Slco1a6 Slco1a6 34 Car12 Atp6v1g3 BC035947
10 Slco1a6 Ces1f Ces1f 35 Aspdh Ehd3 Igfbp5
11 Ces1f Hbb-bt Hbb-bt 36 Akr1c14 Hexb Atp6v1g3
12 Hbb-bt Egf Snhg11 37 Kdr Slc12a1 Nrp1
13 Snhg11 Snhg11 Tmigd1 38 Atp6v1g3 BC035947 Slc13a1
14 Tmigd1 Tmigd1 Egf 39 Hsd11b2 Slc13a1 Slc12a1
15 Acsm3 Acsm3 Acsm3 40 Hexb Col6a6 Col6a6
16 Slc22a30 Slc22a30 Slc22a30 41 Eng Gm4450 Gm4450
17 Gm11128 Cyp2a4 Gm11128 42 BC035947 Kdr Adamts15
18 Aqp2 Hba-a2 Cyp2a4 43 Pi16 Adamts15 Ehd3
19 Cyp2a4 Aqp2 Hba-a2 44 Slc13a1 Hsd11b2 Aspa
20 Fxyd4 Aqp1 Gm5424 45 Col6a6 Aspa Mogat1
21 Emcn Gm5424 Slc17a1 46 Gm4450 Apela D630029K05Rik
22 Aqp1 Slc17a1 Aqp1 47 Egfl7 Mogat1 Gm15638
23 Hba-a2 Plpp1 Aqp2 48 Adamts15 D630029K05Rik Hsd11b2
24 Ly6c1 Fxyd4 Slc12a3 49 Meis2 Eng Akr1c18
25 Slc17a1 Emcn Fxyd4 50 Aspa Gm15638 Smlr1
PT DCT CD-IC LOH CD-PC Endo Podo
Neutro T lymph Macro Fib B lymph NK
Table 13: Top 100 genes with highest weights in the mouse kidney analysis in Step 2 of the
tree-guided deconvolution procedure (separated by epithelial and immune cells). The bulk
data are from Beckerman et al. (2017), Craciun et al. (2016). and Arvaniti et al. (2016)
and the single cell reference is obtained by 7 healthy mice from Park et al. (2018). This
table is color-coded by marker genes.
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A.2.9. Tables of high-weighted genes from pancreatic islet analysis and mouse kidney anal-
ysis
A.3. Supplementary Information for cell type specific differential expression via de-
convolution
A.3.1. Null distribution validation on Xin et al. (2016) artificial dataset
The validation part utilized only 12 healthy subjects from Xin et al. (2016). We randomly
assign diseased and healthy labels 100 times (L = 100) for 12 subjects (6 healthy and
6 diseased). To get the p-values from null distribution, We utilized the same R = 100
repetitions of gene subsets as in 4.3. There are 141 out of 20127 genes shows zero expression
for the 12 healthy subjects and those zero-expressed genes are deleted in the null validation
analysis. Before deleting, we matched those 141 genes to DE genes chosen by our method.
Most of those genes (101 out of 141) overlapped with genes chosen by our method before
the adjustment of variances.
For the 19986 genes tested in null validation, we first draw the QQ-plot for average p-values
across repetitions (Figure 28). The best matched genes and worst match genes are shown
in Figure 28. They actually lines pretty well as a line. However, not exactly on the x = y
line.
Those are not the genes that we are most interested in. We are more interested in genes
that are actually cell type specific expressed but not selected by our method. For each cell
type, we showed QQ-plot for 10 genes that are not selected from our method.
From those plots, there is a motivation to relax the assumption of µg and σg and include
them as parameters in our model.
We estimated the ρˆg, σˆ2g and µˆg from equations (4.10-4.10) and their distribution are shown
in Figure 33. From the histogram, we can model ρg with beta distribution, σ
2
g with gamma
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Figure 28: QQ plots of genes with best fit of uniform distribution or worst fit of uniform
distribution.
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Figure 29: QQ plots of DE genes in alpha cells selected by DESeq 2, but not selected by
MuSiC-DE.
Figure 30: QQ plots of DE genes in beta cells selected by DESeq 2, but not selected by
MuSiC-DE.
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Figure 31: QQ plots of DE genes in delta cells selected by DESeq 2, but not selected by
MuSiC-DE.
Figure 32: QQ plots of DE genes in gamma cells selected by DESeq 2, but not selected by
MuSiC-DE.
97
Figure 33: Estimated parameters from null distribution.
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distribution and µg with normal distribution with mean zero. After that, we can use
empirical Bayes estimated ρg, σ
2
g and µg to test for DE.
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